Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy

Chandra Sekhar Boddupalli1†, Shiny Nair1†, Glenn Belinsky1, Joseph Gans2, Erin Teeple3, Tri-Hung Nguyen2, Sameet Mehta3, Lilu Guo2, Martin L Kramer2, Jiapeng Ruan1, Honggge Wang2, Matthew Davison2, Dinesh Kumar2, DJ Vidyadhara4, Bailin Zhang2, Katherine Klinger2, Pramod K Mistry1,5*

1Department of Internal Medicine, Yale School of Medicine, New Haven, United States; 2Translational Sciences, Sanofi, Framingham, United States; 3Yale Center for Genome Analysis, Yale School of Medicine, New Haven, United States; 4Department of Neuroscience, Yale School of Medicine, New Haven, United States; 5Department of Molecular & Cellular Physiology, Yale School of Medicine, New Haven, United States

Abstract:

Background: Neuronopathic Gaucher disease (nGD) is a rare neurodegenerative disorder caused by biallelic mutations in GBA and buildup of glycosphingolipids in lysosomes. Neuronal injury and cell death are prominent pathological features; however, the role of GBA in individual cell types and involvement of microglia, blood-derived macrophages, and immune infiltrates in nGD pathophysiology remains enigmatic.

Methods: Here, using single-cell resolution of mouse nGD brains, lipidomics, and newly generated biomarkers, we found induction of neuroinflammation pathways involving microglia, NK cells, astrocytes, and neurons.

Results: Targeted rescue of Gba in microglia and neurons, respectively, in Gba-deficient, nGD mice reversed the buildup of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph), concomitant with amelioration of neuroinflammation, reduced serum neurofilament light chain (Nf-L), and improved survival. Serum GlcSph concentration was correlated with serum Nf-L and ApoE in nGD mouse models as well as in GD patients. Gba rescue in microglia/macrophage compartment prolonged survival, which was further enhanced upon treatment with brain-permeant inhibitor of glucosylceramide synthase, effects mediated via improved glycosphingolipid homeostasis, and reversal of neuroinflammation involving activation of microglia, brain macrophages, and NK cells.

Conclusions: Together, our study delineates individual cellular effects of Gba deficiency in nGD brains, highlighting the central role of neuroinflammation driven by microglia activation. Brain-permeant small-molecule inhibitor of glucosylceramide synthase reduced the accumulation of bioactive glycosphingolipids, concomitant with amelioration of neuroinflammation involving microglia, NK cells, astrocytes, and neurons. Our findings advance nGD disease biology whilst identifying compelling biomarkers of nGD to improve patient management, enrich clinical trials, and illuminate therapeutic targets.

Funding: Research grant from Sanofi; other support includes R01NS110354.

*For correspondence: pramod.mistry@yale.edu
†These authors contributed equally to this work
Competing interest: See page 28
Funding: See page 28
Received: 28 April 2022
Preprinted: 16 May 2022
Accepted: 08 July 2022
Published: 16 August 2022
Reviewing Editor: Mone Zaidi, Icahn School of Medicine at Mount Sinai, United States

© Copyright Boddupalli, Nair et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Editor’s evaluation
The pathophysiology of neuropathic Gaucher disease (nGD) is far from clear. This study not only provides mechanistic insights into the processes underpinning microglial activation and neuroinflammation but also implicates glucosylceramide in the pathogenesis of nGD through the use of a novel inhibitor. Overall, the landmark study substantially improves our understanding of nGD with significant therapeutic ramifications.

Introduction
In Gaucher disease (GD), biallelic mutations in GBA underlie defective acid β-glucosidase (glucocerebrosidase, GCase) and buildup of the primary substrate, glucosylceramide (GluCer), and its inflammatory metabolite glucosylsphingosine (GlcSph) in the lysosomes (Grabowski et al., 2021). GD is classified into three broad phenotypes based on the absence (type 1 GD, GD1) or onset of early-onset neurodegeneration in childhood (fulminating GD type 2, GD2, and slower chronic neurodegeneration, GD3). Adults with GD1 have a markedly increased risk of Parkinson’s disease and Lewy body dementia (PD/LBD) (Bultron et al., 2010; Grabowski et al., 2021). Moreover, heterozygous carriers of GBA mutations are at an increased risk of PD/LBD (Aharon-Peretz et al., 2004; Sidransky and Lopez, 2012; Sidransky et al., 2009). Notably, low GCase is reported in the brains of sporadic PD patients who do not harbor GBA mutations (Gegg et al., 2022). Together, GBA variants and GCase deficiency are important determinants of a wide spectrum of neurodegenerative diseases.

Glucosylceramide and glucosylsphingosine display potent inflammatory and immunogenic activities (Nagata et al., 2017; Nair et al., 2015; Nair et al., 2016; Pandey et al., 2017). Treatment of non-neuronopathic GD1 involves enzyme replacement therapy (ERT) targeted to the macrophages via mannose receptors and substrate reduction therapies (SRTs) using inhibitors of glucosylceramide synthase (GCS) (Cox et al., 2000; Mistry et al., 2017a; Mistry et al., 2017b; Platt et al., 2018). However, currently, there are no effective therapies for the devastating neurodegenerative sequela of GBA mutations. In GD1, SRT is predicated on the concept that the rate of synthesis of GluCer is reduced to match residual enzyme activity due to GBA mutations (Platt et al., 2018). However, in neurodegenerative GD2 and GD3, residual glucocerebrosidase activity is profoundly depressed due to severe GBA mutations. A randomized-controlled trial of brain-penetrant SRT, N-butyldeoxynojirimycin, in patients’ GD3 was unsuccessful in ameliorating neurological manifestations. However, N-butyldoxynojirimycin is a relatively weak inhibitor of GCS with significant off-target effects (Schifffmann et al., 2008). Using a more specific, brain-penetrant GCS inhibitor in a chemically induced model of nGD, some disease pathways were ameliorated on bulk RNA analysis, but had no effect on inflammatory pathways (Blumenreich et al., 2021).

Microglia are specialized, self-renewing, CNS-resident macrophages that represent the dominant immune cells involved in maintaining CNS homeostasis. Emerging data from single-cell analysis and genome-wide association studies of several neurodegenerative diseases have revealed a central role of microglia in neurodegeneration (Chen and Colonna, 2021a). Although several mechanisms have been proposed to explain neurodegeneration associated with GBA mutations, most studies in GD have focused on GBA deficiency in neurons, while contribution of other cell types in driving the disease pathology has been considered minor (Cho et al., 2019; Vitner et al., 2015). Immunohistochemical evidence of microglial alteration have been reported in neuronopathic GD, but the effect of GBA deficiency in microglia per se is not understood. Further studies are warranted to investigate the immune landscape of nGD to clearly delineate therapeutic targets and generate biomarkers.

Hitherto, studies aimed at understanding the mechanisms of neuroinflammation in neurodegeneration due to GBA deficiency have solely relied on bulk cell population analysis, which have hindered the delineation of heterogeneity and complexity of the immune milieu within the brain as well as the role of GBA in individual cell types of the brain. Here, we applied an integrated approach based on novel mouse models, lipidomic analyses, scRNA-seq of immune cells, and brain snRNA-seq to decipher temporospatial components of neuroinflammation associated with GBA deficiency including immune cell subsets, activated pathways, as well as probe therapeutic targets and discover novel biomarkers. Importantly, we used both early-onset neuronopathic GD mice Gba<sup>exnl</sup> (loxP-stop-loxP) mice, with a germline deletion of Gba (henceforth referred to as nGD mice) which phenocopies human GD2, fulminating neuronopathic GD (Enquist et al., 2007) as well as a new mouse model of microglia-specific Gba
deletion in Gba<sup>fl/fl</sup> mice that mimics the late-onset progression seen in some patients with GD1. To further understand the function of Gba in microglial and neuronal homeostasis and disease progression, we developed additional new nGD mouse models with microglia and neuron-specific rescue of Gba.

We evaluated brain-penetrant inhibitor of GCS as a therapeutic strategy in both early- and late-onset nGD models to assess its impact on reducing cellular glycosphingolipids, individual components of neuroinflammation and neurodegeneration while elucidating temporospatial cellular events. Our findings define a previously unreported role of glycosphingolipid-laden microglia and macrophages along with NK cells and astrocytes in neurodegeneration associated with Gba deficiency while also revealing novel biomarkers and therapeutic targets.

### Methods

| Key resources table |
|---------------------|
| **Reagent type (species) or resource** | **Designation** | **Source or reference** | **Identifiers** | **Additional information** |
| Antibody | CD11b | BD Biosciences | 583,553 | (1:1000) |
| Antibody | CD11b | BD Biosciences | 552,850 | (1:1000) |
| Antibody | ACSA-2 | Miltenyi Biotec | 130-123-284 | (1:100) |
| Antibody | CD45 | Biolegend | 103,133 | (1:1000) |
| Antibody | NK1.1 | BD Biosciences | 562,864 | (1:250) |
| Antibody | CCR2 | R and D | FAB5538F | (1:100) |
| Antibody | CD3 | Biolegend | 100,241 | (1:250) |
| Antibody | NK1.1 | Biolegend | 108,753 | (1:250) |
| Antibody | 1 A/1-E | Biolegend | 107,639 | (1:1000) |
| Antibody | CD4 | BD Biosciences | 563,790 | (1:500) |
| Antibody | CD4 | BD Biosciences | 558,107 | (1:1000) |
| Antibody | Gr-1 | Biolegend | 108,440 | (1:1000) |
| Antibody | Ly-6C | Invitrogen | 47-5932-82 | (1:1000) |
| Antibody | CD64 | Biolegend | 139,306 | (1:200) |
| Antibody | B220 | eBioscience | 47-0452-80 | (1:200) |
| Antibody | CD8a | eBioscience | 56-0081-82 | (1:1000) |
| Antibody | IL-1Beta | Invitrogen | 17-7114-80 | (1:1000) |
| Antibody | IFNy | Biolegend | 505,808 | (1:250) |
| Antibody | IFNy | BD Biosciences | 562,020 | (1:250) |
| Other | Brdu Flow kit | BD Pharmingen | 51-9000019AK | |
| Other | 5-Bromo-2’-deoxyuridine | Cayam Chemical Company | 15,580 | 180 µg/ml (injected) and 800 µg/ml (in water) |
| Other | Cell Rox Deep Red kit | Invitrogen | C10422 | |

### Patients

Stored serum samples of GD patients were analyzed. All patients had diagnosis of GD based on <10% of normal leucocyte acid-β glucosidase activity. The study was approved by the Human Investigations Committee of Yale School of Medicine. 51 patients had type 1 GD with at least one N370S (pArg409Ser) mutation in GBA gene, mean age 63.9 years (range 40–93 years). Patients were stratified into young and older patients with mean age 11.25 years vs. 55.8 years. Five patients had GD type 3 (homozygous for L444P mutation, pLeu483Leu). The mean age of 28 healthy controls was 38 years.
Mice

Mice were housed in the animal facility of Yale University in New Haven. All animal experiments were conducted in compliance with institutional regulations under authorized protocol (2016-10872) approved by the Institutional Animal Care and Use Committee. Gba<sup>lsl/lsl</sup> mice or Krt14<sup>lnl/lnl</sup> were generated as described previously (Enquist et al., 2007). We refer to Gba<sup>lsl/lsl</sup> as nGD mice throughout the text. We used Krt14<sup>Cre</sup> (strain #: 018964), Cx3cr1<sup>Cre</sup> (strain #: 025524), and Nes<sup>tin Cre</sup> (strain #: 003771) obtained from Jackson Laboratories. For breeding purpose, we used Gba<sup>lnl/wt</sup> mice (gift from Sanofi Genzyme) that were then crossed with Krt14<sup>Cre/Cre</sup> (Jackson Laboratories) to obtain Gba<sup>lsl/wt Krt14 cre/cre</sup>. These mice were used as parents to obtain nGD, Gba<sup>lsl/wt</sup>, and Gba<sup>wt/wt</sup> pups. nGD Cx3cr1<sup>Cre/+</sup> and nGD Nes<sup>Cre/+</sup> were obtained by breeding these parents on to Cx3cr1<sup>Cre</sup> and Nes<sup>Cre</sup>. Gba<sup>fl/fl</sup> Cx3cr1<sup>cre</sup> mice were generated by crossing Gba<sup>fl/fl</sup> (Mistry et al., 2010) with Cx3cr1<sup>Cre</sup> mice obtained from Jackson Laboratories. Mice of both sexes were used for the study. From postnatal day 8, C57BL/6J mice (Jackson Laboratories, USA) were injected intraperitoneally (i.p.) daily with 25 mg conduritol β-epoxide (CBE) (Calbiochem Millipore, Darmstadt, Germany) per kilogram body weight, or with phosphate-buffered saline (PBS) (Vardi et al., 2020). Newborn mice were gavaged daily with 5 mg/kg of GZ 161 once a day starting at postnatal day 4 (Cabrera-Salazar et al., 2012). To determine whether further benefits could be achieved by prenatal exposure to GZ 161, a subset of mice also received GZ 161 in food using a formulation calculated to provide 20 mg/kg/day.

Brain tissue harvesting and cell preparation

The complete brain was cut into small pieces and incubated with digestion buffer (RPMI supplemented with 2% FBS, 2 mM HEPES, 0.4 mg/ml Collagenase D, and 2 mg/ml DNase) for 30 min at 37°C under shaking. To stop enzymatic digestion, EDTA 5 mM was used and the sample was homogenized with a syringe. This was then followed by gradient centrifugation, and cell separation was achieved via Percoll gradients (GE Healthcare Life Sciences) of various densities (Lee and Tansey, 2013). Myelin was then removed by vacuum suction and cells were isolated from the interphase. The interphase was diluted with 10 ml of HBSS and centrifuged at 500 × g for 7 min to obtain cell pellet that was used for cellular analysis.

Flow cytometry

Fluorochrome-labeled antibodies used for the flow cytometry are listed in the Key resources table. In brief, surface staining was performed ex vivo using antibodies to CD11b, CD45, Gr-1, CD3, CD8, CD4, CD103, CD69, and NK1.1 (BD Biosciences); ACSA-2 antibody (Miltenyi Biotech). For staining of the intracellular antigens, GZM-A and Pro IL-1β (BD Biosciences) cells were stimulated with cell stimulation cocktail (eBioscience) for 4 hr. After surface staining with antibodies, cells were fixed and permeabilized using BD cytofix and Cytoperm and antibodies recognizing GZM-A and Pro IL-1β.

Sorting of cells by flow cytometry

Isolated total brain cells were resuspended at 1 million cells/ml of PBS and Live/Dead Fixable Violet Dead Cell Stain (Thermo Fisher) for 10 min to exclude nonviable cells. Cells were washed once in excess PBS, and then, cells were suspended in ice-cold FACS buffer (10% FBS in PBS with 1% HEPES + 0.5% EDTA) and stained with anti-mouse CD45 and anti-mouse CD11b antibody (BD Pharmingen) for 30 min at 4°C. All cells were washed twice with FACS buffer and sorted into polypropylene tubes with 500 μl of ice-cold FACS buffer. All samples were acquired on the BD FACS Aria.

Single-cell RNA sequencing (scRNA-seq)

All cells were prepared through 10X Genomics V3 3′ Gene Expression kit and sequenced on NovaSeq flow cells to achieve high read depth. We used the preprocessed digital gene expression matrices as obtained from cell ranger (as run by the YCGA sequencing core facility). These matrices were processed using Seurat (Satija et al., 2015). The clusters were determined using Louvain algorithm for community detection (Vincent et al., 2008). Differential gene expression between the clusters was carried out using the MAST method (Finak et al., 2015). The visualizations and analysis were carried out in R (R Core Team). The data were visualized as t-distributed stochastic neighbor embedding (t-SNE) (Hinton, 2002). From 14-day pups, we sequenced a total of 4895 CD45+ cells. For GZ161
treatment experiments, we sequenced a total of 40,763 CD45+ cells that consists of four groups of mice with three mice per each group.

Subsetting of microglia cells
Based on the clustering of CD45+ cells, clusters 1, 16, and 26 were kept for final analysis. The clusters were selected based on the microglial gene expression. The clusters comprised 4230 cells. Scoring used z-scores of homeostatic microglia genes, DAM genes from Wang et al., 2020.

Single-nuclear RNA sequencing (snRNA-seq)

Nuclei isolation
Brain tissue samples were stored at –80°C. For tissue lysis and washing of nuclei, sample sections were added to 1 ml lysis buffer (Nuclei PURE Lysis Buffer, Sigma) and thawed on ice. Samples were then Dounce homogenized with PestleAx20 and PestleBx20 before transfer to a new tube, with the addition of additional lysis buffer. Following incubation on ice for 15 min, samples were then filtered using a 30 µM MACS strainer (MACS strainer, Fisher Scientific), centrifuged at 500 × g for 5 min at 4°C using a swinging bucket rotor (Sorvall Legend RT, Thermo Fisher), and then pellets were washed with an additional 1 ml cold lysis buffer and incubated on ice for an additional 5 min. Lysates were combined with 1.8 ml of a 1.8 M sucrose solution (Nuclei PURE Sucrose Buffer, Sigma) containing 1 mM DTT and 0.2 U RNAse inhibitor and mixed by inversion. Samples were then layered on top of a 1.8 M sucrose layer to form a gradient and centrifuged at 30,000 × g for 45 min at 4°C using a swinging bucket rotor. The supernatant was removed, and nuclei pellets were resuspended in 1 ml of a 1× PBS wash buffer containing 1% BSA and 0.2 U RNAse inhibitor. Samples were centrifuged again at 500 × g for 5 min at 4°C and the supernatant removed. Nuclei were resuspended in 0.5 ml wash buffer and counted using Countess (Life Technologies) prior to 10X Genomics protocol. For samples that were enriched using flow cytometry, nuclei were stained with 20 μg/ml DAPI for 30 min on ice with occasional mixing. Nuclei were centrifuged at 500 × g for 5 min at 4°C. The supernatant was removed, and pellet resuspended in 800 µl of a 1× PBS wash buffer containing 1% BSA, 1 mM EDTA, and 0.2 U RNAse inhibitor. Nuclei were sorted using the BD Influx by first gating on forward/side scatter then on DAPI-positive nuclei. The collected nuclei were centrifuged, then resuspended in ~200 µl 1× PBS wash buffer containing 1% BSA and 0.2 U RNAse inhibitor and counted using Countess (Life Technologies) prior to 10X Genomics protocol.

Library preparation and NovaSeq sequencing
Libraries were prepared according to 10X Genomics protocol using the Chromium Next GEM Single Cell 3′ Reagents Kit V3.1 (Dual Index) for encapsulation, mRNA capture, CDNA synthesis/amplification, and library construction. Final libraries were quantified using the DNA High Sensitivity Kit (Agilent Bioanalyzer 2100) and Qubit 2.0 (Life Technologies). Libraries were diluted to 1.5 nM, then pooled prior to sequencing on the Illumina NovaSeq6000. UMI count matrices were generated with Cell Ranger V3.0.2.

Data preprocessing
Summary information for final UMI count matrices for nuclei by individual sample and sequencing data is presented in (Figure 5—figure supplement 1A, C). Count matrices together with nucleus barcodes and gene labels were loaded with R version 3.6.1/RSstudio for sample integration and unsupervised clustering using Seurat Package version 3.1. For quality control (QC), nuclei were filtered following standard protocols based on examination of violin plots. Cutoffs were used, and the filtered matrices were then individually log-normalized by sample according to standard Seurat workflows. After quality filtering, total nuclei were included in the final data analysis.

Broad cell-type annotation
Sample integration was performed in Seurat using the Find Integration Anchors and Integrate Data functions for variable features. Following integration and scaling according to Seurat package workflows, a range of clustering resolution values were trialed prior to broad cell-type annotation; UMAP, t-SNE plots for broad types annotation included. Cluster-level expression of major cell type
markers was examined and used to annotate cells contained within each cluster. Clustering resolution achieved separation and consistency of cell-type marker expression.

Differential gene expression and pathway enrichment analysis

Genes differentially expressed between conditions within clusters may reveal pathway alterations specific to the clustered cell type. To profile cluster-level pathway enrichment patterns, cluster-level differentially expressed genes were identified using the Seurat Find Markers function with the MAST package. Markers used for downstream functional analysis were those with adjusted p-value <0.05. Functional ontology analysis by cluster was performed for each cluster marker set using ingenuity pathway analysis (IPA) (enrichment-adjusted p-value < 0.05).

Total RNA-seq

mRNA sequence data were uploaded to a high-performance computing system with PartekFlow software (v7.0, Partek, St. Louis, MO), adapter trimmed and remapped to mouse genome, mm10 using STAR v2.5.3a aligner with default setting (Phred:20) for read mapping. Statistical analysis was carried out using false discovery rate (FDR) correction through the Benjamini–Hochberg method.

BrdU retention assay

The assay was performed as described earlier (Takizawa et al., 2011); briefly mice were i.p. injected with 180 μg BrdU (sigma) and were fed water containing 800 μg/ml BrdU and 4% glucose for 12 days. Mice were then sacrificed, organs (brain and spleen) were removed, and cells were isolated as described earlier. BrdU staining was performed using BrdU labeling kit (BD). Cells from normal water-fed mice were used as staining controls.

Mouse serum Nf-L assay

Quanterix Nf-L assays were performed in triplicate according to the manufacturer’s protocols using the Nf-Light Advantage kit on a single-molecule array (SIMOA) HD-X instrument (Quanterix, Lexington, MA).

Lipidomics

Separation of glucosylerceramides and galactosyl ceramides was performed by SFC-MS/MS analyses at the MUSC Lipidomics Shared Resource. The equipment consisted of a Waters UPC 2 system coupled to a Thermo Scientific Quantum Access Max triple quadrupole mass spectrometer equipped with an ESI probe operating in the multiple reaction monitoring-positive ion mode tuned and optimized for the Waters UPC 2 system.

Brain tissue slide preparation and MALDI-MS imaging

Brain tissues were dissected, divided sagittally into halves and immediately placed in Cryomolds (Tissue-Tek) containing 10% gelatin-water (porcine skin, Sigma-Aldrich, #G1890), placed at 37°C on the heating block, and transferred to the cryomold into dry-ice bath. Cryo-sectioning was performed at a chamber temperature of –20°C with 12 μm thickness. Sections were thaw-mounted onto the ITO-coated side with barcoding of MALDI IntelliSlides (Bruker, Cat# 1868957). Slides were stored at –80°C until time for imaging. An optical image for tissue sections was obtained using TissueScout scanner (Bruker). Once the optical image was obtained, it was transferred to the HTX Sublimator (HTX Technologies, Chapel Hill, NC) for matrix deposition. DHB (2,5-dihydroxybenzoic acid) was applied on the tissue sections by sublimation, which was performed according to the HTX Sublimator setting (2 ml of 40 mg/mL DHB in acetone transfer solvent, 60°C preheat temperature, 160°C final temperature, 200 s). MALDI-MS imaging was performed in positive ion mode over a mass range of m/z 300–1300 on a Bruker timsTOF fleX mass spectrometer equipped with a 10 kHz SmartBeam 3D Nd:YAG (355 mm) laser. Imaging was performed using a laser raster size of 20 μm custom setting, 20 μm scan range, with trapped ion mobility mode On (tims’ON’) for cross-sectional collision values with the following parameters: 1/K, start at 0.90 V/s/cm² and end 1.70 V/s/cm², ramp time at 150 ms, accumulation time 40.0 ms, duty cycle 26.67%, ramp rate 6.50 Hz. Spectra were accumulated from 400 laser shots with the laser power percentage adjusted using the highest peak (m/z 760 positive ion mode) intensity between 10⁴ and 10⁵, and the method was saved for all subsequent acquisitions. For each image
acquisition, the instruments were calibrated using ESI-L Low concentration tuning mix (Agilent Technologies, Cat #G1969-85000). Data were analyzed using SCILs Lab MALDI imaging software package, version 2021b (Bruker), with data normalized to the TIC. Targeted analysis for hexceramides, sphingomyelins, and phosphatidylcholines was analyzed for differential changes between animals.

**Lipid extraction of mouse serum**

To quantify GlcSph, 7 μl of mouse serum was aliquoted into a labeled 1.5 ml Eppendorf tube followed by 100 μl of internal standard solution (12 ng/ml dimethyl-psycho sine, 80% methanol, 20% acetonitrile with 10 mM ammonium acetate, and 1% formic acid). The samples were vortexed for 5 min and sonicated for 10 min. The tubes were centrifuged at 13,000 × g for 5 min at room temperature (RT). The supernatant from each tube was transferred into a pre-labeled total recovery MS vial. Calibration curves for GlcSph were prepared in a pooled control serum, and concentrations of lysoGL1 were from 0.1 to 1000 ng/ml.

**Mass spectrometry analysis of GlcSph**

Mouse serum was first tested on a Hilic- method to separate psycho sine (stereoisomer of GlcSph) and GlcSph and confirm that psychosine does not interfere with the quantitation of mouse serum glucosylsphingosine levels (Wei-Lien Chuang et al.). The supernatant was injected (5 μl) into an LC/MS/MS system comprised of an Acquity UPLC (Waters, Milford, MA) and Sciex Triple Quad 5000 mass spectrometer (Sciex, Toronto, Canada). The chromatographic separation was achieved with a Waters Acquity BEH C18 column (2.1 × 150 mm, 1.7 μm) using mobile phases: (A) water with 0.1% formic acid and (B) 85:15 MeOH:ACN with 0.1% formic acid. The column was maintained at 60°C. GlcSph was eluted with the following gradient: from 50% B to 99% B over 2 min, then the mobile phase composition was held constant for 1 min followed by a rapid return (0.1 min) to 50% B maintained for 0.5 min. All experiments were carried out at a flow rate of 0.5 ml/min. Data were analyzed in Analyst (AB Sciex, Toronto, Canada).

**Behavioral studies**

**Balance beam test**

Evaluating fine motor coordination using balance beam (1 mt) with 12 mm width resting 50 cm above the top of the pole. The time to cross each beam was recorded and compared between mouse strains.

**Open field**

Mouse locomotor behavior was assessed using the open field (Crusio, 2001). Mice were individually placed on the 28 × 28 cm plate surrounded by plastic walls in a well-lit room and allowed to freely explore for 10 min. Spatial statistic, total distance travel, area measure, and time spent in the center of the square were quantified. The movements were recorded with a video tracking system and stored on a computer.

**BODIPY staining**

Isolated total mice brain cells from nGD and age-matched control mice were prepared (as described in the section ‘Brain tissue harvesting and cell preparation’) and stained with CD45, CD11b, and ACSA-2, then incubated in PBS with BODIPY 493/503 (1:1000 from a 1 mg/ml stock solution in DMSO; Thermo Fisher) for 10 min at RT, washed twice in PBS, and BODIPY intensity was analyzed on LSRII instrument (BD Biosciences).

**ROS assay**

To assess ROS generation in astrocytes and microglia from nGD mice, isolated total mice brain cells were stained with CD45, CD11b, and ACSA-2 followed by incubation in FACS buffer with CellROX Deep Red (1:500; Invitrogen) for 30 min at 37°C, washed twice in FACS buffer, and CellROX Deep Red Intensity was analyzed on LSRII instrument (BD Biosciences).
ApoE measurement
ApoE levels in sera of GD patients were measured by ELISA using Abnova Cat# KA1031 following the manufacturer’s instructions. A dilution of 1:400 sera was used.

Quantification and statistical analysis
Data were routinely presented as mean ± SEM. Statistical significance was determined using t-test using Bonferroni–Dunn correction for multiple comparisons. Differences between groups were analyzed using Student’s t-test using GraphPad Prism 8.0. For the Kaplan–Meier analysis of survival, the log-rank (Mantel–Cox) test was performed.

Study approval
All animal experiments were conducted in compliance with institutional regulations under authorized protocol (2016-10872) approved by the Institutional Animal Care and Use Committee. The study was approved by the Human Investigations Committee of Yale School of Medicine, and written informed consent was received prior to participation.

| Reagents  | Supplier name     | Cat#   | Clone   |
|-----------|-------------------|--------|---------|
| CD11b     | BD Biosciences    | 583553 | M1/70   |
| CD11b     | BD Biosciences    | 552850 | M1/70   |
| ACSA-2    | Miltenyi Biotech  | 130-123-284 | IH3-18A3 |
| CD45      | BioLegend         | 103133 | 30-F11  |
| NK1.1     | BD Biosciences    | 562864 | PK136   |
| CCR2      | R&D               | FAB5538F |
| CD3       | BioLegend         | 100241 | 17A2    |
| NK1.1     | BioLegend         | 108753 | PK136   |
| 1A/1-E    | BioLegend         | 107639 | M5%/114.152 |
| CD4       | BD Biosciences    | 563790 | GK1.5   |
| CD4       | BD Biosciences    | 558107 | RM4-5   |
| Gr-1      | BioLegend         | 108440 | RB6-8c5 |
| Ly-6C     | Invitrogen        | 47-5932-82 | HK1.4  |
| CD64      | BioLegend         | 139306 | X54-5   |
| B220      | eBioscience       | 47-0452-80 | RA3-6B2 |
| CD8a      | eBioscience       | 56-0081-82 | 53-6.7  |
| Brdu Flow kit | BD Pharmingen   | 51-9000019AK |
| 5-Bromo-2′-deoxyuridine | Cayman Chemical Company | 15580   |
| Cell Rox Deep Red | Invitrogen   | C10422   |
| IL-1Beta  | Invitrogen        | 17-7114-80 | NTTEN3 |

Results
Glycosphingolipid-laden microglial activation and immune cell infiltration drive GD-associated neurodegeneration
We performed temporospatial analysis of brain in nGD mice (Gba<sup>lsl/lsl</sup> mice with germline deletion of Gba, rescued from lethal skin phenotype using Krt14<sup>Cre</sup>) compared to control mice (Gba<sup>lsl/wt</sup> and Gba<sup>wt/wt</sup>) on days 2, 4, 8, 10, and 14. nGD mice looked clinically well during the first week and subsequently developed progressive ataxia, weight loss, and hind limb paralysis, by day 14, as described previously (Enquist et al., 2007). Microglia and macrophage subsets in brain were defined by combinatorial expression of CD11b,
CD45, T cell immunoglobulin and mucin domain containing 4 (TIMD4), and the chemokine receptor C-C motif chemokine receptor 2 (CCR2). Brain microglia have self-renewal capacity with minimal monocyte input in contrast to CCR2+ macrophages, which have limited self-renewal capacity and are constantly replaced by blood monocytes (Dick et al., 2022). Infiltration of CCR2+ macrophages (MFs) defined as CD11bhiCD45+CCR2+CD64+ TIMD4+ population (Figure 1—figure supplement 1A) was noted in the nGD brain from an early time point day 2, which showed a steady increase until day 14 when the mice reached the humane end point (Figure 1A). Concurrently, there was attrition of homeostatic microglia and incremental infiltration of diverse immune cells into nGD brains, which coincided with mice displaying clear signs of neurodegeneration (Figure 1A and B, Figure 1—figure supplement 1A). The predominant immune cells in healthy mouse brains were homeostatic microglia, as well as in nGD brains, the repertoire of immune cells comprised diverse lymphoid (T cells, NK cells, ILC-2, pDC), and myeloid compartment (cDC, monocytes, and/or macrophages) (Figure 1—figure supplement 1B). To investigate the metabolic consequences of Gba deletion in microglia and infiltrating immune cells, we performed HPLC/MS/MS on flow-sorted microglia and infiltrating immune cells. Microglia from nGD brains harbored elevated levels of GluCer species (C16, C18, and C20), as well as GlcSph. Notably, the immune cell infiltrates in the nGD brains were also enriched in glucosylceramides (C16 and C18) (Figure 1—figure supplement 1C).

For de novo characterization of the brain immune cell microenvironment, sorted CD45+ cells from nGD and control brains were analyzed by scRNA-seq. Dimensionality reduction using t-distributed stochastic neighbor embedding (t-SNE) analysis revealed 15 distinct cellular clusters of CD45+ cells (numbered 0–14) (Figure 1C). We assigned these clusters to individual immune subsets based on the expression of known marker genes (Figure 1C, Figure 1—figure supplement 1D and E). There were major alterations in the immune cell composition in nGD brains, which was qualitatively and quantitatively dominated by various lymphocyte populations (T cells, yT cells, Treg cells, NK cells, and ILC-2), pDC, and a heterogenous myeloid compartment (cDC, monocytes/macrophages, and granulocytes) (Figure 1C, Figure 1—figure supplement 1D). Homeostatic microglia were reduced in nGD brains, consistent with impaired microglial homeostasis in nGD pathology (Figure 1—figure supplement 1A and D). Interestingly, the B cell population (cluster 4) appeared more pronounced in nGD brains, although it was also present in controls. The microglia and immune cell infiltrates in nGD brains exhibited a striking upregulation of type 1 interferon signature genes (ISG) (Figure 1D). Total RNA-seq analysis performed on flow-sorted microglia from nGD and control mice revealed distinct gene expression profiles in GluCer/GlcSph-laden nGD microglia vs. control microglia (Figure 1—figure supplement 2A). Microglia of nGD mice exhibited clear downregulation of homeostatic genes and concomitant upregulation of disease-associated microglia (DAM) signature genes, in addition to upregulation of ISGs (Figure 1—figure supplement 2B and C). Together, these findings establish GluCer/GlcSph-laden DAM, and peripheral immune cell infiltration as key features of nGD neuropathology.

**Gba restoration in microglia and neurons prolongs survival of nGD mice**

To dissect the contribution of microglia and neurons in nGD neurodegeneration, we generated nGD Cx3cr1Cre+ and nGD NesCre+ mice for selective rescue of Gba in microglia and neurons, respectively (Figure 2A, Figure 2—figure supplement 1A). Unless otherwise stated, we used littermate Gba+/+ with the respective Cre recombinases as controls. Notably, restoration of Gba in microglia (nGD Cx3cr1Cre+Gba+ mice) led to more than twofold increase in survival compared to nGD mice (Figure 2B). Selective restoration of Gba in neurons (nGD NesCre+ mice) further enhanced the survival up to ~200 days where they reached the humane end point (Figure 2B). To assess the alterations in microglia and macrophage phenotypes associated with targeting of Gba in microglia/neurons, we compared the brains of nGD, nGD Cx3cr1Cre+, and nGD NesCre+ mice. Restoration of Gba in microglia of nGD mice (nGD Cx3cr1Cre+) resulted in increased homeostatic microglia with reduction in CCR2+ MFs and peripheral immune cell infiltration compared to nGD brains (Figure 2C, Figure 2—figure supplement 1B). In contrast, restoration of Gba in neurons of nGD mice (nGD NesCre+) blocked attrition of microglia as well as the infiltration of CCR2+ MFs and peripheral immune cells (Figure 2C). Correspondingly, induction of intracellular Pro-IL-1β in microglia, an indicator of microglial activation, was observed in both nGD and nGD Cx3cr1Cre+ brains (Figure 2D and E) but not in nGD NesCre+ brains (Figure 2D and F, Figure 2—figure supplement 1C). Collectively, these data establish the critical role of Gba deficiency in neurons in aiding vigorous microglial activation and immune cell infiltration in nGD and nGD Cx3cr1Cre+ brains. Consistent with this notion, compared to nGD mice, both nGD Cx3cr1Cre+ mice and
Figure 1. Loss of Gba induces microglial activation and immune cell infiltration in neuronopathic Gaucher disease (nGD) brain. (A) Fluorescence-activated cell sorting (FACS) analysis of the whole brain of Gba<sup>wt/wt</sup>, Gba<sup>lsl/wt</sup>, and nGD (Gba<sup>lsl/lsl</sup>) mice performed at indicated days. The gates indicate cell populations revealed by CD11b and CD45 expression: CCR2<sup>+</sup> MFs (CD11b<sup>hi</sup>CD45<sup>+</sup>), microglia (CD11b<sup>lo</sup>CD45<sup>+</sup>), and immune infiltrates (CD11b<sup>lo</sup>CD45<sup>hi</sup>). The data is representative of three independent experiments. (B) Bar graph compares percentage of CCR2<sup>+</sup> MFS, microglia, and immune infiltrates.
Figure 1 continued

between Gba<sup>wt/wt</sup>, Gba<sup>h/h</sup>, and nGD mice brain (n = 6–8 mice/group); statistical significance was determined using t-test with using Bonferroni–Dunn correction for multiple comparisons (***p<0.0001). (C) t-distributed stochastic neighbor embedding (t-SNE) plot depicting different microglial and non-microglial cell subsets. The clusters are coded based on their mice affiliation (on left). In total, 14 clusters containing 6 microglia clusters and 9 clusters of immune cells (on right). (D) Hierarchical clustering of differentially expressed genes associated with type 1 IFN genes from nGD mice vs. the control mice. p<0.05 was considered significant (two-sided t-tests). All individual type 1 IFN genes with significant differential expression are listed on right. Error bars represent means ± SEM; p-values were calculated with Welch’s t-test (**p<0.001 and ***p<0.0001).

The online version of this article includes the following figure supplement(s) for figure 1:

Figure supplement 1. Loss of Gba disrupts microglial homeostasis and induces damage-associated microglia (DAM) phenotype and immune cell infiltration in neuronopathic Gaucher disease (nGD) (Gba<sup>h/h</sup>) brain.

Figure supplement 2. Total RNA-seq analysis performed on flow-sorted microglia in neuronopathic Gaucher disease (nGD) (Gba<sup>h/h</sup>) and wild-type mice.

nGD Nes<sup>Cx3cr1<sup>Cre/+</sup></sup> mice showed striking reduction of brain glucosylceramides (by ≥90% for C16 and C18:1, and by 50–70% for C18, C20:1, C22, C22:1, C24, and C24:1, and by 38% for C20 glucosylceramide) with a concomitant, striking reduction of GlcSph (89–98%, shown in Figure 2G). We depict this data, as fold elevation compared to wild-type mice brains, of various glucosylceramides in nGD and after Gba rescue in microglia and neurons in Figure 2—figure supplement 2A, which provides insight into relative contributions of microglia and neurons in the accumulation of the lipids in nGD. First, in Gba deficiency, the microglia display impressive capacity to process accumulating glucosylceramides, and second, that the major source of accumulating glucosylceramides in nGD appears to be the neuronal compartment. This is illustrated by the observation that compared to wild-type mice brains, in nGD mice, there is a 200-fold elevation of brain C16-glucosylceramide, which falls to 5-fold elevation after microglia rescue and to 2.4-fold after neuronal rescue of Gba. Similar gradations are seen for brain GlcSph accumulation: 200-fold vs. 20-fold vs. 7-fold, respectively. Together, these observations suggest that reduced sphingolipid turnover observed in nGD Nes<sup>Cx3cr1<sup>Cre/+</sup></sup> mice may exert a positive effect on overall microglial maintenance regardless of microglia cell intrinsic Gba deficiency. It seems likely that diverse inflammatory responses triggered by sphingolipid-induced neuronal damage observed in nGD and nGD Cx3cr1<sup>T<sub>Gba<sup>h/h</sup></sub></sup>/<sup>T<sub>Gba<sup>h/h</sup></sub></sup> brains could directly impact microglial maintenance and cell death.

As expected, there was no change in the levels of galactosylceramide (GalCer) species or galactosylsphingosine (GalSph) in nGD brains (Figure 2—figure supplement 2B). MALDI imaging of frozen brain sagittal sections was performed to assess the topography of GSL accumulation. Elevated levels of numerous hexosylceramides (HexCers) were detected in nGD brains. Of these, HexCer (18:1/22:0) exhibited higher signal intensity in the cerebral cortex and midbrain region of nGD Cx3cr1<sup>T<sub>Gba<sup>h/h</sup></sub></sup> brains compared to control mice (Figure 2—figure supplement 2C). Similarly, HexCer (18:1/20:0) species was elevated in the same brain regions of nGD Nes<sup>Cx3cr1<sup>Cre/+</sup></sup> mice (Figure 2—figure supplement 2D). Interestingly, a co-regulated lipid in GD cell models, lysophosphatidylcholine (LysoPC) (Bodennec et al., 2002), showed striking accumulation in the cerebral cortex and midbrain region of nGD Cx3cr1<sup>T<sub>Gba<sup>h/h</sup></sub></sup> and nGD Nes<sup>Cx3cr1<sup>Cre/+</sup></sup> mice (Figure 2—figure supplement 2F and G, lower panel). Assessment of motor balance and coordination showed that the longer-lived adult nGD Nes<sup>Cx3cr1<sup>Cre/+</sup></sup> (4–6 months) mice were unable to complete the balance beam runs with an average time >60 s (Figure 2—figure supplement 2E). Notably, there were unusual repetitive circling body movements (Figure 2—figure supplement 2F). These features appear to phenocopy behavioral disorders reported in human GD3 (Abdelwahab et al., 2017). Taken together, these results indicate the differential role of Gba in individual cell types in the brain. Notably, reconstituting Gba in microglia of nGD mice affords an impressive capacity to offset toxic lipid accumulation in the brain and significantly prolong survival.

Selective deletion of Gba in microglia results in late-onset neurodegeneration

To further establish the role of Gba in microglia, we used our Gba floxed mice (Mistry et al., 2010) for microglia-specific Gba deletion using Cx3cr1-Cre (Yona et al., 2013) (Gba<sup>fl/fl</sup>Cx3cr1<sup>Cre/+</sup>) (Figure 3—figure supplement 1A). We investigated this mouse strain for clinical phenotype, brain GluCer/GlcSph accumulation, neuroinflammation, and whether microglia/macrophages underwent compensatory recycling in the setting of microglia-specific Gba deficiency. Remarkably, Gba<sup>fl/fl</sup>Cx3cr1<sup>Cre/+</sup> brains showed a pronounced accumulation of GlcSph and several GluCer species (C16, C18, C20, and C22 GluCer species) compared
Figure 2. Gba deficiency in neurons aids in microglial activation and immune cell infiltration. (A) Schematic showing overview of the mouse models and methods used in the study. (B) Kaplan–Meier survival analysis of neuronopathic Gaucher disease (nGD), nGD Cx3cr1<sup>Cre<sup>+/</sup></sup>, and nGD Nes<sup>Cre<sup>+/</sup></sup> mice cohorts with their respective littermate controls (n = 5–6 mice/group) using log-rank (Mantel–Cox) test (**p<0.0001). (C) Bar graph shows comparison of percentage of CCR2<sup>+</sup> MFs, microglia and immune infiltrates between nGD, nGD Cx3cr1<sup>Cre<sup>+/</sup></sup>, and nGD Nes<sup>Cre<sup>+/</sup></sup> mice with littermate controls (n =

Figure 2 continued on next page
3–6 mice/group). Bar graph showing percentage of Pro-IL-1ß+ microglia cells in (D) nGD vs. control mice (n = 5–6/group), (E) nGD Cx3cr1Cre/+ vs. control mice (n = 5–6/group), and (F) nGD NesCre+/− vs. the control mice (n = 3 mice/group). (G) Quantitative analysis of total glucosylceramide (GluCer) species and glucosylsphingosine (GlcSph) levels by LC-ESI-MS/MS in nGD, nGD Cx3cr1Cre/+ mice, and nGD NesCre+/− mice brain compared with the control mice (n = 4–8 mice/group). (C–G) show representative data from two independent experiments using controls. Means ± SEM are shown. Unpaired t-test, two-tailed was used to test significance. *p<0.05, **p<0.001, and ***p<0.0001.

The online version of this article includes the following source data and figure supplement(s) for figure 2:

**Figure supplement 1.** Restoring Gba function in microglia and neurons enhances neuronopathic Gaucher disease (nGD) mice survival.

**Figure supplement 1—source data 1.** Gel image showing genotype of neuronopathic Gaucher disease (nGD) mice (n = 5–6/group), and (F) Nes neuronopathic Gaucher disease (nGD) mice (n = 3 mice/group).

**Figure supplement 1—source data 2.** Gel image showing genotype of neuronopathic Gaucher disease (nGD) Cx3cr1Cre/+ and wild-type (wt) mice.

**Figure supplement 1—source data 3.** Gel image showing genotype of nGD NesCre+/− mice and wild-type (wt) mice.

**Figure supplement 1—source data 4.** Gel image showing removal of lsl (lox-stop-lox) cassette in neuronopathic Gaucher disease (nGD) mice in various tissues due to Krt14Cre expression.

**Figure supplement 1—source data 5.** Gel image showing Cx3cr1Cre enabled removal of the lsl (lox-stop-lox) cassette in different tissues of neuronopathic Gaucher disease (nGD) Cx3cr1Cre/+ mice.

**Figure supplement 1—source data 6.** Gel image showing NesCre enabled removal of the lsl (lox-stop-lox) cassette in brain of neuronopathic Gaucher disease (nGD) NesCre−/− mice.

**Figure supplement 2.** Analysis of lipids in neuronopathic Gaucher disease (nGD), nGD Cx3cr1Cre/+, and nGD NesCre+/− mice brain and behavioral studies.

to control brains (Figure 3A). There was no change in the levels of GalCer or GalSph species (Figure 3—figure supplement 1B). Young mice appeared healthy despite accumulation of GluCer/GlcSph in the brain, but aged Gbafl/flCx3cr1Cre/− mice (~12 months old) started to exhibit motor deficits manifested by a longer time to complete the beam walk and increased tendency to slip (data not shown). HPLC-MS/MS analysis revealed elevated levels of GlcSph in the sera of young Gbafl/flCx3cr1Cre/− mice (6–8 weeks), which tended to increase further in aged (14 months) mice compared to healthy controls (Figure 3B). Congruently, there was a significant reduction in microglia and increase in CCR2+ MFs and immune cell infiltration in aged Gbafl/flCx3cr1Cre/− mice, while no changes were observed in young Gbafl/flCx3cr1Cre/− mice (Figure 3C). We attributed increase of infiltrating CCR2+ MFs in aged Gbafl/flCx3cr1Cre/− mice brain compared to young mice to higher turnover rate as seen by BrdU uptake assay (Figure 3—figure supplement 1C and D). In contrast to nGD mice with florid neuroinflammation, we could not detect Pro IL-1ß induction in microglia of Gbafl/flCx3cr1Cre/− mice (Figure 3—figure supplement 1E). We isolated FACS-sorted microglia from young and aged Gbafl/flCx3cr1Cre/− brains to perform scRNA-seq. A total of 2302 microglial cell transcriptionomes were subjected to Louvain clustering, resulting in nine transcriptionally distinct microglial states (Figure 3D). The proportion of individual microglial clusters were differentially enriched in young vs. aged mice brain (Figure 3E). Taking advantage of the single-cell resolution of our data and published microglia-specific lineage genes (Chen and Colonna, 2021a; Chen et al., 2021b; Wang et al., 2020), we identified homeostatic microglial clusters (0, 2, 3, and 6), DAM clusters (1 and 4), and hitherto undescribed Gba locus-associated gene cluster (cluster 5, we refer to it as homeostatic microglia represented by clusters 0, 2, 3, and 6 were the predominant microglia population (Figure 3F). Notably, in aged Gbafl/flCx3cr1Cre/− brains, DAM signature clusters (1 and 4), along with the Gba locus-associated gene cluster (cluster 5) and interferon-induced gene cluster (cluster 7), represented the major microglial populations (Figure 3F). Therefore, with aging transition of homeostatic microglia (cluster 2) into DAM microglia cluster with higher expression of DAM genes (ApoE, Spp1, Lpl, Ccl3, and Cst7) and lower levels of homeostasis genes (P2ry12 and Tmem119) was evident (Figure 3G). Aged Gbafl/flCx3cr1Cre/− microglia also expressed higher levels of chemokines (Ccl3, Ccl4, Ccl2, etc.), inflammatory molecules (Tnf, Il1a, and Il1b), and key DAM signature genes (ApoE, Spp1, Lpl, Ccl3, and Cst7) (Figure 3G). Notably, CCL2/CCR2 interaction mediates the recruitment ofCCR2-bearing leukocytes in the brain in several neuroinflammatory diseases (Mahad et al., 2008). In this context, aged Gbafl/flCx3cr1Cre/− mice microglia displaying higher expression of Ccl2 and other inflammatory chemokines may mediate infiltration of peripheral CCR2+ MFs and leukocytes contributing to neuroinflammation seen in our late-onset neurodegeneration model, akin to that seen in some GD1 patients with aging (Belarbi et al., 2020). Interestingly, expression of Mtx1 and Thbs3 genes that are assigned to chromosome 1q21 contiguous with Gba was enriched in cluster 5 and prominent in agedGbafl/flCx3cr1 microglia (we have termed these...
Figure 3. Aged Gba<sup>fl/fl</sup>Cx3cr<sup>Cre/+</sup> mice brain show alteration of microglia subsets and neurodegeneration. (A) Quantitative analysis of total glucosylceramide/glucosylsphingosine (GluCer/GlcSph) levels in Gba<sup>fl/fl</sup>Cx3cr<sup>Cre/+</sup> mice and control mice (n = 3 mice/group). Statistical significance was determined using t-test using Bonferroni–Dunn correction for multiple comparisons (*p<0.05, **p<0.001, and ***p<0.0001). (B) Quantitative analysis of serum GlcSph levels in young and aged Gba<sup>fl/fl</sup>Cx3cr<sup>Cre/+</sup> mice and control mice (n = 8–11 mice/group; repeated at least three times). (C) Bar graph Figure 3 continued on next page
Figure supplement 1—source data 1. Gel image showing genotype of Gba<sup>fl/fl</sup> Cx3cr1<sup>Cre</sup> mice showing comparison of percentage of CCR2<sup>+</sup> MFs, microglia, and immune infiltrates between young and aged mice. Means ± SEM are shown. Unpaired t-test, two-tailed was used to test significance *p<0.05, **p<0.001, and ***p<0.0001.

Figure supplement 1. Changes in microglia subsets coupled with neurodegeneration are seen in aged Gba<sup>fl/fl</sup> Cx3cr1<sup>Cre</sup> mice. The online version of this article includes the following source data and figure supplement(s) for figure 3:

Figure 3 continued

shows comparison of percentage of CCR2<sup>+</sup> MFs, microglia, and immune infiltrates between young and aged Gba<sup>fl/fl</sup> Cx3cr1<sup>Cre</sup> mice and control mice (n = 3 mice/group, repeated at least three times). (D) UMAP plots show clustering of microglia from young and aged Gba<sup>fl/fl</sup> Cx3cr1<sup>Cre</sup> mice. Cells are colored by cluster (left) and age (right). (E) Hierarchical heat map depicting differential expression of genes taken from Wang et al. and compared between microglia cluster from young and aged Gba<sup>fl/fl</sup> Cx3cr1<sup>Cre</sup> mice. (F) Fraction of cells for each cluster present in young and aged Gba<sup>fl/fl</sup> Cx3cr1<sup>Cre</sup> mice, respectively. (G) Gene expression heat map for clusters defined as microglia. (A, B) Data represents three biological replicates. Means ± SEM are shown. Unpaired t-test, two-tailed was used to test significance *p<0.05, **p<0.001, and ***p<0.0001.

The online version of this article includes the following source data and figure supplement(s) for figure 3:

Figure supplement 1. Changes in microglia subsets coupled with neurodegeneration are seen in aged Gba<sup>fl/fl</sup> Cx3cr1<sup>Cre</sup> mice brain.

Figure supplement 1—source data 1. Gel image showing genotype of Gba<sup>fl/fl</sup> Cx3cr1<sup>Cre</sup> mice having conditional deletion of the Gba gene through Cx3cr1<sup>Cre</sup> expression.

Gba-associated genes). The expression of IFN response genes in microglia cluster 7 remained unchanged between young and aged mice (Figure 3E). Taken together, molecular elucidation of aged Gba-deficient microglia shows a loss of homeostatic signature with pronounced expression of inflammatory signaling molecules. Thus, our findings highlight the important role of Gba in long-term maintenance of microglial homeostasis and implicates GBA deficient microglia in the development of age-related neurodegenerative disease like PD that occurs with high risk in adults with GD1.

**NK cells, together with microglial activation, drive neuropathology in nGD brains**

Analysis of immune cell infiltrates by scRNA-seq in the brains of nGD and nGD Cx3cr1<sup>Cre</sup> mice revealed significant infiltration of NK cells (Fig. S1B and E). We confirmed striking NK infiltration in nGD brains by flow cytometry (Figure 4A–C). Brain-infiltrating NK cells expressed granzyme A (GzmA) (Figure 4D–F). Interestingly, higher percentages of NK cell infiltration were observed in nGD Cx3cr1<sup>Cre</sup> mice compared to nGD mice brain. It should be noted that there is increased attrition/death of microglia in nGD mice compared to nGD Cx3cr1<sup>Cre</sup> mice. Taking these observations into consideration, we surmise that inflammatory cytokines and chemokines secreted by activated microglia that are present in higher proportion in nGD Cx3cr1<sup>Cre</sup> mice might stimulate NK cell infiltration in brains than seen in nGD mice. NK cell frequency and GzmA expression were unaltered in the spleens of both nGD and nGD Cx3cr1<sup>Cre</sup> mice (Figure 4—figure supplement 1A, Figure 4G and H), implying that the primary cues responsible for activation of NK cells were emanating from within the nGD brains. Sphingosine 1-phosphate (Sph-1P) plays a key role in NK cell trafficking via its receptor S1P5 (Walzer et al., 2007). To address whether Sph-1P is involved in NK cell infiltration in nGD brain, we performed HPLC-MS/MS analysis of brain tissue for sphingosine species. We found no specific buildup of sphingosine lipid species including Sph-1P in nGD and nGD Cx3cr1<sup>Cre</sup> mice brains compared to the control mice (Figure 4—figure supplement 1B), suggesting that other mechanism(s) may underlie NK cell infiltration or that there is local generation of S1P that is beyond the resolution of HPLC-MS/MS.

To assess whether the pattern of neuroinflammation observed in genetic models of nGD could be replicated in another system, we used a chemically induced model of nGD using an inhibitor of acid β-glucosidase (CBE). Administration of CBE in WT mice resulted in the nGD phenotype, as described previously (Farfel-Becker et al., 2011; Kanfer et al., 1982). FACS analysis of immune cells in the brains of CBE-treated mice revealed major infiltration of immune cells (Figure 4I, Figure 4—figure supplement 1C) as well as Pro-IL-1ß induction in the microglia (Figure 4J). Like genetic models, immune cell phenotyping in the brains of CBE-treated mice showed striking induction of GzmA<sup>+</sup> NK cells (Figure 4K and L, Figure 4—figure supplement 1C). Therefore, using genetic and chemically induced nGD mouse models, we confirmed a conserved immune landscape of nGD brains comprising prominent NK cell infiltration and microglial activation.

**Single-cell resolution revealed role of microglial Gba in delaying neuroinflammation**

To gain a comprehensive and dynamic overview of the underlying mechanisms involved in the longitudinal course of GD-associated neurodegeneration, we performed brain single-nucleus RNA-seq to
**Figure 4.** NK cell infiltration into the brain of neuronopathic Gaucher disease (nGD), nGD Cx3cr1<sup>Cre/+</sup> mice. (A) CD45<sup>+</sup> cells form the whole brain of nGD, nGD Cx3cr1<sup>Cox/</sup>, and control mice were gated to analyze CD3 NK1.1<sup>+</sup> NK cells. Bar graphs represent the percentage of NK cells in the immune infiltrates of (B) nGD mice brain (n = 5 mice/group) and (C) nGD Cx3cr1<sup>Cox/</sup> mice brain, respectively (n = 4 mice/group). (D) Expression of granzyme A (GzmA) in the brain infiltrating NK cells of nGD and nGD Cx3cr1<sup>Cox/</sup> mice. Bar graphs compare the percentage of GzmA<sup>+</sup> NK cells in the immune infiltrates of (E) nGD mice brain (n = 5 mice/group) and (F) nGD Cx3cr1<sup>Cox/</sup> mice brain, respectively (n = 4 mice/group). (G) Percentage of NK cells in the spleen of WT, nGD, and Cx3cr1<sup>Cox/</sup> mice. (H) Percentage of GzmA<sup>+</sup> NK cells in the spleen of WT, nGD, and Cx3cr1<sup>Cox/</sup> mice. (I) Percentage of immune infiltrates in the brain of B6, PBS, and CBE. (J) Percentage of Pro-IL-1β<sup>+</sup> microglia cells in the brain of B6, PBS, and CBE. (K) Percentage of NK cells in the brain of B6, PBS, and CBE. (L) Percentage of GzmA<sup>+</sup> NK cells in the immune infiltrates of (E) nGD mice brain (n = 5 mice/group) and (F) nGD Cx3cr1<sup>Cox/</sup> mice brain, respectively (n = 4 mice/group). Bar graphs compare the percentage of GzmA<sup>+</sup> NK cells in the immune infiltrates of (E) nGD mice brain (n = 5 mice/group) and (F) nGD Cx3cr1<sup>Cox/</sup> mice brain, respectively (n = 4 mice/group).
Figure 4 continued

nGD vs. control mouse brain (n = 5 mice/group) and (F) nGD Cx3cr1Cre/+ vs. control mouse brain, respectively (n = 4 mice/group). Percentage of NK1.1+ NK cells and GzmA+ NK cells in the spleen of (G) nGD mice and (H) nGD Cx3cr1Cre/+ mice (n = 4–5 mice/group). Bar graph showing percentage of (I) immune infiltrates (J) Pro-IL-1ß+ microglia cells (K) percentage of NK cells and (L) GzmA+ NK cells in the whole brain of Gba<sup>wt/wt</sup> treated with vehicle or conduritol β-epoxide (CBE). Experiments were repeated three times. (A) and (D) were representative from one of the experiments, (B), (C), (E–L) Data are combined from two such experiments. Data are shown as means ± SEM. Unpaired t-test, two-tailed was used to test significance. *p<0.05, **p<0.001, and ***p<0.0001.

The online version of this article includes the following figure supplement(s) for figure 4:

Figure supplement 1. NK cell infiltration into the brain of neuronopathic Gaucher disease (nGD), nGD Cx3cr1<sup>Cre/+</sup> mice.

elucidate cell types/pathways in three experimental settings: (1) the acute neuropathic model nGD mice at 2 weeks, (2) after restoration of Gba in microglia (nGD Cx3cr1<sup>Cre/+</sup>) at early asymptomatic stage (2 weeks) and late stage (6 weeks) when it displays overt neurodegenerative phenotype, and (3) late-onset model, nGD Nes<sup>Cre/+</sup> brains with rescue of Gba in neuronal compartment (age ~7 months).

Integrated hierarchical analysis with quality controls (Figure 5—figure supplement 1A) revealed 61 distinct cell clusters that were annotated for major cell types based on the differential expression of canonical marker genes (Figure 5A, Figure 5—figure supplement 1B). We focused on four distinct gene sets: lysosomal biology, ISGs, chemokines, and ApoE. Lipid metabolism genes are known to be upregulated in DAMs. We found on ApoE because of its established roles in both lipid transport and neurodegeneration highlighted by GD (Serrano-Pozo et al., 2021). AUCell analysis was applied to interrogate these gene set enrichments and stratify different cell types: lysosomal biology (Abca2, Ap1b1, Ap31, Ap45, Atg6v0a1, Atg6v1h, Cd63, Cd68, Cln3, Ctsb, Ctsd, Ctsl, Cts, Galc, Galectins, Hexa, Hexb, Lamp, Psap, Slc17a5, Sumf1, Gpr37, Gpr37l1, Mtx1, and Thbs3); interferon signaling genes (Psmb10, Psmb9, Psmb8, Psma4, Psme2, Oas1a, Oas1b, Oas1l, Isg15, Irf207, Irf1, Irf123, Iftm3, Ift3, Ift35, Epst1, Parp14, Bst2, Irf7, Irf9, Stat1, Stat2, Usp18, Irf2, Sfn5, and Ift1); chemokine genes (Cxc10, Cxc12, Ccl5, Cxcl5, Ccl2, Ccl3, and Ccl7); and ApoE. In the brains of nGD and 6-week-old nGD Cx3cr1<sup>Cre/+</sup> mice both with overt neurodegenerative phenotypes, lysosomal biology, ISG, and ApoE genes were highly upregulated in microglia, Purkinje, oligodendrocytes (clusters 2, 34, and 36), astrocytes (clusters 22, 23, 4, 48, 52, and 9), and neurons (0, 3, 5, and 6) (Figure 5B).

In contrast, microglia of 2-week-old nGD Cx3cr1<sup>Cre/+</sup> mice were similar to controls. In line with these observations, DAM markers were significantly enriched in microglia from both nGD and 6-week-old nGD Cx3cr1<sup>Cre/+</sup> compared to 2-week-old nGD Cx3cr1<sup>Cre/+</sup> mice (Figure 5—figure supplement 1C), consolidating the importance of microglial Gba in ameliorating neurodegeneration seen in florid acute neuroinflammation. Importantly, the results suggest that even in setting of normal microglia Gba in nGD Cx3cr1<sup>Cre/+</sup> mice, increased flux of glucosylceramide lipids arising from Gba-deficient neuronal cells leads to DAM over time as seen at 6 weeks but not at 2 weeks in these mice. Gba rescue in the neuronal compartment resulted in the normalization of pathways associated with lysosomal biology, ISG, and ApoE microglia genes were highly upregulated in microglia, Purkinje, oligodendrocytes (clusters 2, 34, and 36), astrocytes (clusters 22, 23, 4, 48, 52, and 9), and neurons (0, 3, 5, and 6) (Figure 5B).

Gene expression analysis revealed that nGD mice exhibited the largest number of differentially expressed genes (DEGs) (n = 19,274), which were strikingly reduced in 2-week-old nGD Cx3cr1<sup>Cre/+</sup> (n = 125) and also in nGD Nes<sup>Cre/+</sup> brains, n = 256 (Figure 5C). Consistent with the neuroinflammation observed in 6-week-old nGD Cx3cr1<sup>Cre/+</sup> mice, elevated DEGs in neuronal clusters were seen (n = 7539) compared to 2-week-old nGD Cx3cr1<sup>Cre/+</sup> mice (n = 125) (Figure 5C). However, 6-week-old nGD Cx3cr1<sup>Cre/+</sup> mice show a reduction of DEGs in different neuronal clusters compared to nGD mice (Figure 5D). Collectively, these results indicate the underlying role of microglial Gba in safeguarding and delaying neuroinflammatory gene networks in nGD brains.

We found evidence of significant activation of several disease pathways in astrocytes (Figure 5B). Astrocytosis has been described in immunohistochemistry of mouse and human neuronopathic brains (Wong et al., 2004). We analyzed the astrocyte compartment for the disease-associated astrocyte (DAA) gene signature (Batiuk et al., 2020; Habib et al., 2020). DAA genes were highly induced in astrocyte clusters from nGD mice and in 6-week-old nGD Cx3cr1<sup>Cre/+</sup> mice but not in 2-week-old nGD Cx3cr1<sup>Cre/+</sup> mice (Figure 5E). IPA was performed on neurons, astrocytes, and microglia. IPA revealed enrichment of necroptosis, interferon, IL8, TREM1, and neuroinflammation signaling pathways
Figure 5. snRNA-seq reveals key role of microglia astrocytes and neurons in Gaucher disease (GD)-associated neuroinflammation. (A) UMAP data from neuronopathic Gaucher disease (nGD) (2 weeks old), nGD Cx3cr1^cre/+ (2 and 6 weeks old, respectively), nGD Nes^Cre/+ mice (n = 3), and corresponding control mice, colored by genotype (top) and cell clusters (bottom). (B) AUC analysis for select lysosome, Interferon signature genes (ISG), chemokine, and Apoe gene sets significantly enriched (false discovery rate [FDR] < 0.05) in microglia, Purkinje, oligodendrocyte, astrocyte, and neuro clusters of Figure 5 continued on next page.
nGD (2 weeks) vs. control mice; nGD Cx3cr1Cre/+ (2 and 6 weeks, respectively) vs. control mice; nGD NesCre/+ mice vs. control mice. Row side bar colors indicate mice genotype, age and cell clusters. (C) Pie chart displays the number of differentially expressed genes (DEGs) in neuronal clusters of nGD (2 weeks) vs. control mice (green); nGD Cx3cr1Cre/+ (2 weeks [orange] and 6 weeks [maroon], respectively); nGD NesCre/+ mice (pink) vs. control mice with log2(fold change) and adjusted p-value < 0.05. Total DEGs from each set of mice are stated in the middle of pie chart with number of DEGs and the neuronal cluster in brackets shown to the right of each pie chart. (D) Bar graph represents the number of DEGs in neuronal clusters of nGD 2 weeks (green) vs. nGD Cx3cr1Cre/+ 6 weeks (maroon) with log2(fold change) and adjusted p-value < 0.05. (E) Heat map of DEGs associated with disease-associated astrocytes (DAA) from nGD; nGD Cx3cr1Cre/+ (2 weeks and 6 weeks, respectively); nGD NesCre/+ mice vs. control mice. p<0.05 was considered significant (two-sided t-tests). All individual DAA genes with significant differential expression are listed on bottom and the astrocyte clusters are shown in right. Red, positive z-score; white, zero z-score; blue, negative z-score. (F) Ingenuity pathway analysis (IPA) from nGD vs. WT. nGD Cx3cr1Cre/+ vs. WT Cx3cr1Cre/+ at 2- and 6-week-old mice; nGD NesCre/+ mice vs. WT NesCre/+ in neuron cluster, microglia, and astrocytes. Orange, positive z-score; white, zero z-score; blue, negative z-score; gray dots are statistically insignificant. (G) Representative flow cytometry histogram (left) and quantification of CellROX fluorescence in astrocytes of nGD mice. (I) Flow cytometry histogram (left) and quantification (right) of CellROX fluorescence in activated and homeostatic microglia from nGD mice. (J) Histogram (left) and quantification (right) of BODIPY fluorescence in activated and homeostatic microglia from nGD mice n = 3–4 mice per group. Data were replicated in at least two independent experiments. Unpaired t-test, two-tailed was used to test significance. *p<0.05, **p<0.001, and ***p<0.0001.

The online version of this article includes the following figure supplement(s) for figure 5:

Figure supplement 1. snRNA-seq analysis of the brain of neuronopathic Gaucher disease (nGD), nGD Cx3cr1Cre/+ mice.

in 2-week-old nGD mice compared to the controls. Gba rescue in microglia of 2-week-old nGD Cx3cr1Cre/+ mice showed abrogation of neuroinflammatory pathways seen in nGD brains (Figure 5F). Between 2 and 6 weeks, as neurodegeneration advanced in nGD Cx3cr1Cre/+ mice, the enrichment of inflammatory pathways was again evident (Figure 5F). Notably, both interferon and NK cell signaling pathways were upregulated in 2-week-old nGD and in 6-week-old nGD Cx3cr1Cre/+ brains (Figure 5F). Consistent with the lack of microglial activation and NK infiltration in nGD NesCre/+ brains (Figure 5F). Pathway analysis of differentially expressed genes revealed that the ‘production of nitric oxide and ROS’ was elevated in nGD and 6-week-old nGD Cx3cr1Cre/+ microglia and astrocytes along with neuroinflammation pathways. Elevated and dysregulated reactive oxygen species (ROS) production from DAM contributes to oxidative stress and has been shown to be intricately linked with neurodegeneration (Mendiola et al., 2020; Takizawa et al., 2011). Consistent with the transcriptional changes observed in nGD mice, astrocytes from nGD mice showed higher fluorescence after treatment with CellROX, indicating a higher level of ROS, compared to astrocytes from control mice (Figure 5G). nGD astrocytes with high ROS level also showed elevated accumulation of neutral lipids, as seen by BODIPY staining (Figure 5H). Moreover, activated microglia in the nGD brain showed enhanced ROS level along with an increased accumulation of lipids compared to homeostatic microglia (Figure 5I and J). Overall, these observations suggest that Gba-deficient neurons and microglia, laden with GlcCer and GlcSph, play key roles in orchestrating neuroinflammation involving astrocytes and NK cells that underlie neurodegeneration in neuronopathic GD.

GCS inhibitor reduces GluCer/GlcSph and reverses microglia and NK cell activation

Collectively our findings suggest that lipid dyshomeostasis and neurodegeneration caused by Gba deficiency in microglia and neurons can be prevented by restoration of Gba. Previous studies have shown that treatment with GCS inhibitor GZ-161 reduced GluCer and GlcSph in the brains of nGD mice and prolonged survival by a few days (Cabrera-Salazar et al., 2012; Figure 6—figure supplement 1A). To determine whether reduction of glucosylceramide lipids by GZ-161 alleviates neuroinflammatory landscape and neurodegeneration, we treated our mouse models with this brain-permeant GCS inhibitor. Consistent with previous studies, GZ-161 treatment significantly prolonged the survival of nGD mice (Figure 6A). We investigated whether GZ-161 treatment could further extend the survival of nGD Cx3cr1Cre/+ mice by more effective reduction of brain GluCer/GlcSph via dual effects of decreased synthesis of GluCer and increased lysosomal degradation of GluCer. Indeed, GZ-161 treatment of nGD Cx3cr1Cre/+ mice resulted in considerable extension of survival compared to untreated mice, with analogous normalization of GlcSph levels in the sera of treated nGD Cx3cr1Cre/+ mice (Figure 6A and B).
Figure 6. Effects of glucosylceramide synthase (GCS) inhibitor (GZ-161) on microglia and GzmA⁺ cells. (A) Kaplan–Meier survival analysis of neuronopathic Gaucher disease (nGD) and nGD Cx3cr1<sup>Cre/+</sup> mice after GZ-161 treatment compared to vehicle-treated controls (n = 4–10 mice/group). (B) Quantitative analysis of serum glucosylsphingosine (GlcSph) levels by LC-ESI-MS/MS in nGD, nGD Cx3cr1<sup>Cre/+</sup> mice with and without GZ-161 treatment compared with the vehicle-treated controls (n = 4–10 mice/group). (C) Representative fluorescence-activated cell sorting (FACS) staining of microglia,
activated microglia, and immune infiltrates in wild-type and nGD mice with and without treatment with GZ-161. (D) Graph represents percentages of microglia, CCR2+ MFs and immune infiltrates in wild-type and nGD mice with and without treatment with GZ-161 (n = 4–6 mice/group). (E) Bar graph showing percentage of Pro-IL-1B+ microglia cells in wild-type and nGD mice with and without treatment with GZ-161 (n = 3–5 mice/group; repeated at least three times). (F) Bar graph showing percentage of Pro-IL-1B+ microglia cells in wild-type and nGD Cx3cr1Cre/+ mice with and without treatment with GZ-161 (n = 3–5 mice/group). (G) Percentage of GzmA+ CD45+ cells in wild-type and nGD Cx3cr1Cre/+ mice with and without treatment with GZ-161 (n = 3–5 mice/group). (H) Bar graphs compare the percentage of NK cells in Gba+/+ and mice treated with conduritol β-epoxide (CBE) and CBE + GZ-161, respectively (n = 3–5 mice/group; repeated at least three times). Data represents three biological replicates. Means ± SEM are shown. Unpaired t-test, two-tailed was used to test significance. *p<0.05, **p<0.001, and ***p<0.0001.

The online version of this article includes the following figure supplement(s) for figure 6:

**Figure supplement 1.** Immune regulatory effects of glucosyl ceramide synthetase (GCS) inhibitor GZ-161 on microglia and GzmA+ cells.

---

Next, we assessed the impact of pharmacological reduction of GluCer/GlcSph on disease-specific, microglial and macrophage phenotypes associated with neuroinflammation in GD mice models. FACS analysis of GZ-161-treated nGD mice showed that the GCS inhibitor significantly reduced the proportion of CCR2+ MFs, concomitantly with restoration of homeostatic microglia compartment (Figure 6C and D). However, GZ-161 treatment had no effect on immune cell infiltrates in the brains of nGD mice (Figure 6C and D). GZ-161 treatment showed a nonsignificant downward trend in microglial Pro-IL-1ß induction in nGD mice (Figure 6B). GZ-161 treatment in longer-lived nGD Cx3cr1Cre/+ mice wherein drug administration was more reliable resulted in significantly increased survival (Figure 6A) accompanied by a reduction in Pro-IL-1ß+ microglia as well as a reduction in GzmA+ immune cells in the brain (Figure 6—figure supplement 1B, Figure 6F and G). We further evaluated the ability of GZ-161 to counteract NK cell induction seen in the CBE model. Administration of GZ-161 in CBE-treated mice reduced infiltration of NK cells in the brain (Figure 6H). Together, these results show that GZ-161 can mitigate the metabolic defect caused by Gba deficiency by reducing the accumulation of GluCer and GlcSph, concurrent with alleviating CNS immune inflammation involving microglia and NK cell activation. Moreover, when microglia are predominantly of homeostatic phenotype through complementation of Gba function in nGD mice, a two-pronged approach of restoring Gba in microglia and GCS inhibitor, the influx of NK cells into the brain and subsequent neurodegeneration is significantly constrained.

**GCS inhibition counteracts age-related microglial dysfunction and NK cell activation**

We investigated whether buildup of GlcCer and GlcSph is proximate cause of neuroinflammation and neurodegeneration in Gba deficiency using the brain-permeant GCS inhibitor in late-onset neurodegeneration Gbafl/flCx3cr1Cre/+ model. The effect of reversing the toxic accumulation of GlucCer/GlcSph on in vivo microglial homeostasis and NK cell activation was assessed by feeding Gba+/+ control mice and Gbafl/flCx3cr1Cre/+ mice with either control or GZ-161-formulated diet, starting at age 3 months, for 7 months. The effect of GZ-161 on GSL accumulation in brain regions was evaluated using MALDI imaging. Gbafl/flCx3cr1Cre/+ mice accumulated HexCer (d18:1/18:0) and HexCer (d18:1/20:0) in the corpus callosum (Figure 7A), which was normalized upon GZ-161 diet. Concomitantly, there was a reduction in HexCer (18:1/22:0) accumulation in the cerebral cortex (Figure 7A).

We performed scRNA-seq of CD45+ cells from brains of Gbafl/flCx3cr1Cre/+ mice and control mice on control or GZ-161-formulated diet. A total of 40,763 CD45+ single-cell transcriptomes were subjected to unsupervised Louvain clustering resulting in a total of 28 transcriptionally distinct populations comprising 10 broad cell types (Figure 7B). Clusters 1, 26, and 16 represented microglia (4230 cells) and were visualized on UMAP, revealing 15 unique clusters (Figure 7B, lower panel). We identified clusters 0, 1, and 5 as homeostatic microglia, cluster 2 as DAM, and cluster 7 as Gba-associated microglia (Figure 7C). DAM cluster 2, which was significantly enriched in Gbafl/flCx3cr1Cre/+ brains, was markedly reduced in Gbafl/flCx3cr1Cre/+ mice fed with GZ-161 diet with concurrent enhancement of homeostatic microglia clusters 0 and 1 (Figure 7D). We found that Gba-associated gene cluster 7 was present exclusively in Gbafl/flCx3cr1Cre/+ mice both on GZ-161 and on the control diet groups. To assess the effect of GZ-161 on NK cells within the brain environment, we further analyzed cluster 17, which represented NK cells (Figure 7—figure supplement 1). GZ-161 treatment resulted in reduction of Gzma, Ccl5, Tyrobp, and Klf2, with no change in Klf1, Klrk1, Cdl2, and Ccl4 (Figure 7E). Collectively, these results demonstrate that GCS inhibitor-mediated reduction
Figure 7. Long-term treatment with glucosylceramide synthase (GCS) inhibitor, GZ-161, counteracts age-related microglial dysfunction and NK cell activation. (A) Signal intensities of hexosylceramides (HexCer) species and lysophosphatidylcholine (LysoPC) identified by MALDI across Gba<sup>fl/fl</sup>Cx3cr<sup>Cre/wt</sup> mice treated with either vehicle or GZ161 and control mice brain. The color bars in MALDI images show signal intensity: blue to yellow indicates low to high levels. (B) UMAP plots show clusters of CD45<sup>+</sup> cells from brain of control and Gba<sup>fl/fl</sup>Cx3cr<sup>Cre/wt</sup> mice treated with either vehicle or GZ161 and control mice.
of GluCer and GlcSph counteracts age-related microglial dysfunction and NK cell activation in several brain regions in Gba<sup>+/−</sup>Cx3cr<sup>Cre/+</sup> mice. Together, these findings not only validate GlcCer/GlcSph as the proximate cause of neuroinflammation involving microglia and NK cells but also point to the potential of brain permeant small-molecule inhibitor as a therapeutic approach for neuronopathic GD.

Generating novel candidate biomarkers of neurodegeneration in Gba deficiency

Given the striking relationship between serum Nf-L, level of pathogenic lipid, GlcSph, and neurodegenerative phenotype, we sought to validate these biomarkers in translational studies in GD patients and explore other potential biomarkers suggested by our results. Lack of circulating biomarkers for pre-symptomatic Gba deficiency-associated neurodegenerative diseases is a major impediment to optimal management of patients and conduct of clinical trials. Therefore, we investigated whether serum levels of neurofilament light (Nf-L), an accepted biomarker of neuroaxonal injury in several neurodegenerative and neuroinflammatory diseases (Gaetani et al., 2019; Khalil et al., 2020; Loeffler et al., 2020; Weinhofer et al., 2021), could serve as a biomarker of neurodegeneration in nGD models. Using ultra-sensitive Quanterix Simoa, we found a massive 2000-fold elevation of serum Nf-L in nGD mice, ~100-fold elevation in nGD Cx3cr<sup>Cre/+</sup>, and ~20-fold elevation in nGD Nes<sup>Cre/+</sup> mice (Figure 8A). Remarkably, GZ-161 treatment, which led to reductions in GlcSph levels, also led to a significant decline in serum Nf-L levels in nGD and nGD Cx3cr<sup>Cre/+</sup> mice (Figure 8A). Serum Nf-L level in nGD mice (18,100 ± 4809 pg/ml) was reduced by GZ-161 treatment to 6876 ± 1080 pg/ml. Conversely, GZ-161 treatment of nGD Cx3cr<sup>Cre/+</sup> mice dramatically reduced Nf-L level to 1297 ± 534.1 pg/ml compared to untreated mice (5466 ± 557.2 pg/ml). The residual Nf-L level after GZ-161 treatment in nGD Cx3cr<sup>Cre/+</sup> mice was significantly lower than that in nGD mice treated with GZ-161, consistent with the synergistic effect of GCS inhibition and restoration of Gba function in microglia (Figure 8A). Increased survival of nGD and nGD Cx3cr<sup>Cre/+</sup> mice after GZ-161 treatment correlated with amelioration of neurodegeneration, as indicated by serum Nf-L levels. Notably, consistent with the age-related progression of neuroaxonal damage, there was a clear age-related increase in serum Nf-L levels with the most significant increase in aged Gba<sup>+/−</sup>Cx3cr<sup>Cre/+</sup> mice (Figure 8B). Serum levels of Nf-L and GlcSph were strongly correlated (r = 0.8344, p<0.0001), consistent with a direct link between lysosomal generation of toxic GlcSph and neuroaxonal injury (Figure 8C). Together, these data support the notion that GlcSph (and GluCer) reduction therapy with the brain-penetrant GCS inhibitor GZ-161 ameliorates neurodegeneration in nGD mice. Moreover, the results suggest that serum Nf-L and GlcSph are promising biomarkers of neurodegeneration in Gba deficiency.

Our findings of serum Nf-L correlating with severity of neurodegeneration as well as serum levels of GlcSph in various permutations of nGD mice model for the first time reveal that such circulating biomarkers may exist not only for tracking the severity of neurodegeneration but also for monitoring the response to therapy. Therefore, we conducted an analysis of several candidate biomarkers of neurodegeneration in patients with GD (Figure 9). We compared serum Nf-L levels in GD3 patients with early mild neurodegenerative symptoms with age-matched GD1 patients who did not develop early-onset neurodegeneration. Serum Nf-L levels were elevated in GD3 patients compared to those in GD1 (Figure 8D). This increase in serum Nf-L levels was associated with elevated serum GlcSph levels in GD3 patients (Figure 8E). Akin to age-related increases in serum Nf-L levels in Gba<sup>+/−</sup>Cx3cr<sup>Cre/+</sup> mice, indicative of age-related progression of neuroaxonal damage (Figure 8B), serum Nf-L levels were significantly elevated in adult GD1 patients compared to children with GD1 and adult healthy controls (Figure 8F). This is significant as adult GD1 patients are at an increased risk of PD/
Figure 8. Clinical evaluation of ApoE and neurofilament light chain (Nf-L) as biomarkers of Gaucher disease (GD)-associated neurodegeneration.

(A) Quantitative analysis of serum Nf-L levels in neuronopathic Gaucher disease (nGD), nGD Cx3cr1<sup>Cre</sup>, and nGD Nes<sup>Cre</sup> mice with and without GZ-161 treatment compared with the vehicle-treated controls (n = 4–10 mice/group; two independent experiments). (B) Comparison of serum Nf-L levels between young and aged Gba<sup>fl/fl</sup> Cx3cr1<sup>Cre/wt</sup> mice along with control mice (n = 8–11 mice/group). (C) Correlation between serum GlcSph and Nf-L levels in GD1 and GD3 mice. (D) Correlation between serum GlcSph and Nf-L levels in young and aged Gba<sup>fl/fl</sup> Cx3cr1<sup>Cre/wt</sup> mice. (E) Comparison of serum ApoE levels between healthy untreated and GZ-161-treated mice. (F) Comparison of serum ApoE levels between pre-ERT and post-ERT mice. (G) Quantitative analysis of LysoPC-16:1 levels in GD1 and GD1 Nes<sup>Cre</sup> mice along with control mice (n = 8–11 mice/group). (H) Correlation between serum GlcSph and Nf-L levels in GD1 and GD1 Nes<sup>Cre</sup> mice. (I) Comparison of serum ApoE levels between healthy untreated and GZ-161-treated mice. (J) Comparison of serum ApoE levels between pre-ERT and post-ERT mice. (K) Correlation between serum GlcSph and ApoE levels. (L) ROC curve analysis for the detection of GD with serum Nf-L levels.

Figure 8 continued on next page.
LBD. Interestingly, LysoPC was present with an exceptionally strong signal in the microglia in the cerebral cortex and midbrain regions of untreated Gba/fl/flCx3cr1Cre/+ mice. Intensity of LysoPC accumulation in brain microglia was significantly reduced by GZ-161 treatment (Figure 8G). The finding of striking LysoPC accumulation in Gba-deficient microglia prompted us to measure LysoPC in the sera of untreated GD1 patients (n = 55) and healthy controls (n = 43). Graph represents ApoE levels in the sera of untreated GD1 patients (n = 55) and after enzyme replacement therapy (ERT) (n = 55). (K) Correlation between serum GlcSph and ApoE levels in sera of GD1 patients. The p-value obtained from Pearson’s correlation test was <0.001 (n = 21 patients). (L) Receiver-operating characteristic (ROC) curves for serum ApoE expression in GD1 patients and area under the curve (AUC). Means ± SEM are shown. Differences between groups were analyzed using unpaired t-test. (A, B) Mann–Whitney test (C, E, H, I), two-tailed. *p<0.05, **p<0.001, and ***p<0.0001.

The online version of this article includes the following figure supplement(s) for figure 8:

Figure supplement 1. Expression of ApoE and Abca1 in different brain cell types of neuronopathic Gaucher disease (nGD) mice.

Figure 9. Remark flowchart. Flow diagram of the study cohort used in the study.
the induction of ApoE is among the key signature genes of DAM. Thus, the role of ApoE in the brain is multifaceted, including lipid homeostasis, modulation of neuroinflammation, and neuronal repair (Serrano-Pozo et al., 2021). Hence, in the context of an inborn error of lipid metabolism exemplified by GD with prominent neurodegeneration, it is highly relevant to explore ApoE expression in various brain cells in different states of nGD. We found prominent ApoE expression in astrocytes and activated microglia in nGD mice. Additionally, there was a striking induction of ApoE in multiple neuronal cell types as well as in endothelial cells (Figure S8—figure supplement 1A). Interestingly, there was concomitant induction of Abca1, suggesting coupling with increased efflux of accumulating pathogenic lipids from cells in Gba deficient brain (Figure S8—figure supplement 1B). Therefore, we measured ApoE in the sera of 55 adults with confirmed GD1 before and after ERT, which dramatically lowered GlcSph and reversed systemic clinical manifestations. Sera of untreated GD1 patients showed markedly increased levels of ApoE compared to healthy control sera (Figure 8I). ERT resulted in a marked decrease in ApoE levels (Figure 8J). Notably, elevated ApoE levels correlated significantly with serum GlcSph levels (Figure 8K). The sensitivity and specificity of ApoE as a biomarker were underscored by the area under the receiver operator characteristic (ROC) of 0.92 (p<0.001) (Figure 8L), similar to that seen in other accepted biomarkers of GD, such as chitotriosidase, gpNMB, and GlcSph (Aerts et al., 2011; Murugesan et al., 2016).

Discussion

There is limited information of how Gba deficiency affects the cross-talk between immune cells and neuronal cell types due to accumulating glucosylceramide lipids. Hence, there are no effective therapies for devastating neurodegenerative diseases associated with Gba mutations, and clinical trials have been severely hindered by a lack of reliable biomarkers. Previous studies in mice have suggested utility of brain permeant GCS inhibitor as treatment for neuronopathic GD but a clinical trial of miglustat (N-butyldeoxynojirimycin), an iminosugar, did not improve neurological end points in GD3 (Schiffmann et al., 2008). Subsequently, more potent GCS inhibitors based on ceramide analogs have shown more promise in genetic nGD model and in chemically induced model (Blumenreich et al., 2021; Cabrera-Salazar et al., 2012; Shayman, 2010; Wilson et al., 2020).

To delineate the impact of glycosphingolipid accumulation, identify candidate biomarkers, and assess the impact of GluCer/GlcSph lowering using a potent inhibitor of GCS, we developed an array of genetic mouse models to probe the cell-specific roles of Gba at single-cell resolution. Our models recapitulated both early- as well as late-onset neurodegenerative GD that provided unique insights through resolving the heterogeneity of brain macrophage populations. Our findings implicate the essential role of GlcCer-laden microglia and immune infiltrates (including CCR2+ MFs defined as CD11bhi CD45^CCR2^ CD64^ TIMD4^ population and NK cells) and astrocytes in orchestrating neuroinflammation. Our studies identified key attributes of GD associated neuroinflammation in the form of attrition of homeostatic microglia, emergence of DAM, influx of CCR2+ MFs, activation of the ISG pathway, and infiltration of activated NK cells. Massive cellular accumulation of GluCer/GlcSph due to Gba deficiency in microglia, immune infiltrates, and neurons resulted in early onset of neuroinflammation, which was attenuated into late-onset neurodegenerative disease by selective rescue of Gba in either microglia or neurons as well as by pharmacological reduction of GluCer/GlcSph in the brain using GCS inhibitor. Interestingly, inflammatory microglia also expressed several proposed biomarkers of GD, which we and others have reported such as complement pathway genes, gpNMB, cathepsin D, and cathepsin S (Afinogenova et al., 2019; Kramer et al., 2016; Mistry et al., 2014; Murugesan et al., 2016; Pandey et al., 2017; Vitner et al., 2010; Zigdon et al., 2015). Rescue of Gba in neuronal progenitors increased survival, but nevertheless, markedly shortened compared to control mice, requiring humane end point sacrifice due to morbid conditions and autistic behavior, reminiscent of human GD3 (Abdelwahab et al., 2017; Bilbo and Stevens, 2017; Wong et al., 2004).

Late-onset neurodegenerative disease observed in some patients with GD1 (Bulton et al., 2010) appeared to be recapitulated in Gba<sup>+/+</sup>Cx3cr1<sup>F<sub>cer</sub></sup> mice having slow progressive neuroinflammation with accumulation of GluCer lipids in the brain, elevated serum NF-L, and DAM gene signatures.

In our nGD mouse models with robust neuroinflammation, we found prominent GzmA<sup+N</sup> NK cell infiltration. Restoring Gba function in microglia alone showed limited effect on NK cell infiltration; however, treatment with GCS inhibitor not only offset GluCer/GlcSph buildup, but also exhibited a novel immunomodulatory effect by abrogating NK cell activation. Therefore, combination therapy
with GCS inhibitors and microglia-targeted therapeutics (Shibuya et al., 2022) merits further exploration. In general, the immune response of NK cells is fine-tuned by a balance of stimulatory and inhibitory signals based on a distinct receptor repertoire. In certain pathological states, injured neurons display activating NKG2D ligands that target them for NK cell-mediated injury (Davies et al., 2019).

A potential mechanism relevant to our findings in nGD for NK cell involvement in neurodegeneration is via HLA-1 recognition by NK cells through its inhibitory receptors Ly49 (in mice) and KIR (in humans), which mediate self/non-self-discrimination (Colonna and Samaridis, 1995; Karlhofer et al., 1992). Thus, downregulation of HLA-1 surface expression is envisioned to trigger NK cell-mediated neuronal injury due to ‘missing self.’ Consistent with this notion, a recent study reported that altered cell surface GSL repertoire limited accessibility of HLA-1 by immune cells, such as CD8 T cells and NK cells, and treatment with a GCS inhibitor (N-butyl-deoxynojirimycin) fully restored accessibility to HLA-1 (Jongsma et al., 2021). Indeed, in our nGD models, a more potent GCS inhibitor, GZ-161, was highly effective in reversing NK cell activation concomitant with marked reduction of brain glucosylceramide lipids. Therefore, it seems likely that in severe Gba deficiency, causing early-onset neurodegeneration, altered cell surface GSLs in neurons impair the accessibility of HLA-1 by NK cell receptors, triggering activation and neuronal degeneration.

Our studies show remarkable efficacy of potent brain penetrant GCS inhibitor, GZ-161, in reducing GluCer and GlcSph in immune and neuronal cells of nGD mice concomitant with amelioration of neuroinflammation and neurodegeneration. A prior clinical trial of GCS inhibitor N-butyldeoxynojirimycin in GD3 showed no effect on neurological symptoms (Schiffmann et al., 2008). In such clinical trials, patients have established advanced neurological disease that can hinder assessment of full therapeutic effects. Therefore, a major unmet need in neurodegenerative disease associated with GBA mutations is the lack of suitable biomarkers to detect neurodegeneration before onset of overt neurological symptoms, such as saccades, ataxia, or seizures. We aimed to leverage the findings from our nGD models to generate novel biomarkers. In our study, neuroaxonal injury was reflected in the elevation of serum Nf-L (Gaetani et al., 2019; Weinhofer et al., 2021). Data from our nGD models with different rates of neurodegeneration revealed Nf-L as a strong serum biomarker of neurodegeneration that correlated with survival as well as with serum GlcSph. The candidacy of these biomarkers is especially bolstered by the finding of rising levels of serum Nf-L and GlcSph in Gba<sup>−/−</sup>Cx3cr<sup>−/−</sup> mice as the source of these biomarkers in these mice is from within the brain. These findings are promising to explore serum NF-L as a biomarker of neurodegeneration to help address significant challenges in the management of patients with GD, that is, distinguish between GD2 and early-onset GD3, track subclinical neurodegeneration in the extremely variable GD3, to help individualize future therapies and identify GD1 individuals at risk for PD/LBD. Indeed, we found that serum NF-L levels were higher in GD3 patients than in age-matched GD1 patients. Moreover, NF-L levels were higher in older patients with GD1 compared to younger patients. This is significant considering that adult GD1 patients are at a risk of developing PD/LBD. In this context, our findings of serum NF-L as a strong biomarker raise the exciting prospect of detecting subclinical neurodegeneration, allowing early initiation of treatment to achieve better clinical outcome. There is an emerging consensus that providing treatment before the onset of overt disease manifestations offers prospects for best outcomes in inborn errors of metabolism. Studying larger cohorts of patients stratified by different types of neurodegenerations due to GBA mutations may aid further biomarker validation. The second promising biomarker emanates from striking induction of ApoE in all neuronal cell types beyond astrocytes and DAM in nGD models. Our translational result of striking elevation of ApoE levels in GD patients that correlates with GlcSph levels is compelling to explore the role of ApoE in neurodegeneration associated with GBA mutations. Indeed, a recent study showed increased prevalence of Apo E4 allele in heterozygote carriers of GBA mutations who develop PD (Shiner et al., 2021).

Overall, through our systematic single-cell transcriptome analysis, we identified cell populations, immunological and pathophysiological mechanisms underlying neurodegeneration associated with GBA deficiency. This approach also yielded therapeutic targets and promising biomarkers for clinical validation to improve patient care and aid clinical trials.

**Limitations of the study**

There are several limitations to our studies. In Gba<sup>hi/hi</sup> model of fulminant neurodegeneration that phenocopies human GD2, GCS inhibitor prolonged survival significantly but the overall effect was...
modest. This is likely related to challenges in administering GCS inhibitor by gavage in the first days of life. While our study showed a critical role for both neuronal and microglial Gba in Gaucher-related neurodegeneration and involvement of NK cells, it was beyond the scope of the current work to delineate a hierarchy of neuronal populations according to their vulnerability to toxic accumulation of lipids in setting of Gba deficiency and compensatory or pathological interactions with glial cells, infiltrating NK cells, and other immune cells. With regard to application of our findings to human health, an earlier randomized trial of GCS inhibitor, N-butyldeoxynojirimycin was not successful in ameliorating neurological symptoms. However, it is a relatively weak inhibitor of GCS with more potent inhibitory off-target effects (Schiffmann et al., 2008). However, more specific and potent GCS inhibitors are showing early promise (Schiffmann et al., 2020; Wilson et al., 2020).

Materials availability
All materials in this study are available upon request.

Acknowledgements
We thank Dr Stefan Karlsson for generously sharing lsl/lsl, nGD mice. We also thank Dr. Sreeganga Chandra for suggestions on mice behavioral tests. This study was funded by a research grant from Sanofi (to PKM).

Additional information

Competing interests
Joseph Gans, Erin Teeple: Tri-Hung Nguyen: "ET is an employee of Sanofi. The author has no other competing interests to declare". Sameet Mehta: T-H N was previously an employee of Sanofi. The author has no other competing interests to declare". Martin L Kramer: LG is an employee of Sanofi and holds stocks in Sanofi. The author has no other competing interests to declare. Jiapeng Ruan: MK was previously an employee of Sanofi and holds stocks in Sanofi. The author has no other competing interests to declare. Matthew Davison: HW was previously an employee of Sanofi. The author has no other competing interests to declare. Dinesh Kumar: HW (now retired) was previously an employee of Sanofi and holds stocks in Sanofi. The author has no other competing interests to declare. Bailin Zhang: BZ is an employee of Sanofi. The author has no other competing interests to declare. Katherine Klinger: KK is an employee of Sanofi. The author has no other competing interests to declare. The other authors declare that no competing interests exist.

Funding

| Funder | Grant reference number | Author          |
|--------|------------------------|-----------------|
| Sanofi | Research grant from Sanofi | Pramod K Mistry |
| National Institute of Neurological Disorders and Stroke | R01NS110354 | Pramod K Mistry |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions
Chandra Sekhar Boddupalli, Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing; Shiny Nair, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing; Glenn Belinsky, Jiapeng Ruan, Formal analysis, Methodology; Joseph Gans, Resources, Data curation, Investigation, Methodology; Erin Teeple, Resources, Data curation, Software, Formal analysis; Tri-Hung Nguyen, Lilu Guo, Martin L Kramer, Formal analysis, Investigation; Sameet Mehta, Honggge Wang, Formal analysis; Matthew Davison, Bailin Zhang, Katherine Klinger, Supervision; Dinesh Kumar, Resources, Software, Formal analysis; DJ Vidyadhara,
Methodology; Pramod K Mistry, Conceptualization, Funding acquisition, Project administration, Writing – review and editing

Author ORCIDs
Chandra Sekhar Boddupalli http://orcid.org/0000-0002-1406-7973
Shiny Nair http://orcid.org/0000-0002-4081-7811
Pramod K Mistry http://orcid.org/0000-0003-3447-6421

Ethics
Human subjects: Informed consent, and consent to publish, was obtained from the patients and the study was approved by the Human Investigations Committee of Yale School of Medicine. Mice were housed in the animal facility of Yale university in New Haven. All animal experiments were conducted in compliance with institutional regulations under authorized protocol (2016-10872) approved by the Institutional Animal Care and Use Committee.

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.79830.sa1
Author response https://doi.org/10.7554/eLife.79830.sa2

Additional files

Supplementary files
• MDAR checklist

Data availability
All data generated or analysed during this study are included in the manuscript and supporting file; source data files have been provided for Figure 2—figure supplement 1 and Figure 3—figure supplement 1. Raw data files for Single cell and single nucleus RNA sequencing are deposited with NCBI GEO under accession numbers GSE207765, GSE207766 and GSE207768.

The following datasets were generated:

| Author(s) | Year | Dataset title | Dataset URL | Database and Identifier |
|-----------|------|---------------|-------------|------------------------|
| Boddupalli CS, Mehta S | 2022 | scRNA seq analysis on immune cells isolated from nGD mice brain | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE207766 | NCBI Gene Expression Omnibus, GSE207766 |
| Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen T-H, Mehta S, Guo L, Kramer ML, Ruan J, Wang H, Davison M, Kumar D, Bailin DJZ, Klinger K, Mistry PK | 2022 | RNA and scRNA seq analyses on immune cells isolated from nGD mice brain | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE207768 | NCBI Gene Expression Omnibus, GSE207768 |
| Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen T-HN, Mehta S, Guo L, Kramer ML, Ruan J, Wang H, Davison M, Kumar D, Vidyadhara DJ, Bailin DJZ, Klinger K, Mistry PK | 2022 | RNA seq analysis on immune cells isolated from nGD mice brain | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE207765 | NCBI Gene Expression Omnibus, GSE207765 |

References
Abdelwahab M, Potegal M, Shapiro EG, Nestrasil I. 2017. Previously unrecognized behavioral phenotype in Gaucher disease type 3. Neurology Genetics 3:e158. DOI: https://doi.org/10.1212/NXG.0000000000000158, PMID: 28634598
Aerts J, Kallemeijn WW, Wedgam W, Joao Ferraz M, van Breemen MJ, Dekker N, Kramer G, Poorthuis BJ, Groener JEM, Cox-Brinkman J, Rombach SM, Hollak CEM, Linthorst GE, Witte MD, Gold H, van der Marel GA,
Overkleeft HS, Boot RG. 2011. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. *Journal of Inherited Metabolic Disease* **34**:605–619. DOI: https://doi.org/10.1007/s10545-011-9308-6, PMID: 21445610

Afinozenova Y, Ruan J, Yang R, Kleytmn N, Pastores G, Lischuk A, Mistky PK. 2019. Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease. *Molecular Genetics and Metabolism* **128**:62–67. DOI: https://doi.org/10.1016/j.mgen.2019.07.014, PMID: 31358474

Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. 2004. Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. *The New England Journal of Medicine* **351**:1972–1977. DOI: https://doi.org/10.1056/NEJMoa033277, PMID: 15525722

Batiuk MY, Martirosyan A, Wahis J, de Vin F, Marneffe C, Kusserow C, Koeppen J, Viana JF, Oliveira JF, Voet T, Ponting CP, Belgard TG, Holt MG. 2020. Identification of region-specific astrocyte subtypes at single cell resolution. *Nature Communications* **11**:1220. DOI: https://doi.org/10.1038/s41467-019-14198-8, PMID: 32139688

Belarbi K, Cuelier E, Bonte MA, Desplancke M, Gressier B, Devos D, Chartier-Harlin MC. 2020. The role of glucocerebrosidase isoenzymes in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide. *FASEB Journal* **16**:1814–1816. DOI: https://doi.org/10.1096/fj.02-0149fje, PMID: 12223447

Bodiennec J, Kacénka K, Rosenbaum H, Gershoni- Baruch R. 2004. Mutations in the glucocerebrosidase gene and Parkinson’s disease in type 1 Gaucher disease. *Journal of Neurochemistry* **156**:692–701. DOI: https://doi.org/10.1111/j.1536-5066.2003.32743826

Embdenec J, Pelled D, Riebeling C, Trajkovic S, Bateman AH. 2002. Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide. *FASEB Journal* **16**:1814–1816. DOI: https://doi.org/10.1096/fj.02-0149fje, PMID: 12223447

Bultron G, Kaena K, Pearson D, Boxer M, Yang R, Sathe S, Pastores G, Mistky PK. 2010. The risk of Parkinson’s disease in type 1 Gaucher disease. *Journal of Inherited Metabolic Disease* **33**:167–173. DOI: https://doi.org/10.1007/s10545-010-9555-0, PMID: 20177787

Cabrera-Salazar MA, Deriso M, Bercury SD, Li L, Lydon JT, Weber W, Pande N, Cromwell MA, Copeland D, Leonard J, Cheng SH, Scheule RK. 2012. Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. *PLOS ONE* **7**:e43310. DOI: https://doi.org/10.1371/journal.pone.0043310, PMID: 22912851

Chen Y, Colonna M. 2021a. Microglia in Alzheimer’s disease at single-cell level: Are there common patterns in humans and mice? *The Journal of Experimental Medicine* **218**:e20202717. DOI: https://doi.org/10.1084/jem.20202717, PMID: 34292312

Chen Y, Liu X, He L. 2021b. The value of long noncoding RNAs for predicting the recurrence of endometriosis: A protocol for meta-analysis and bioinformatics analysis. *Medicine* **100**:e26036. DOI: https://doi.org/10.1097/MD.00000000000026036, PMID: 34032726

Cho SM, Vardi A, Platt N, Futterman AH. 2019. Absence of infiltrating peripheral myeloid cells in the brains of mouse models of lysosomal storage disorders. *Journal of Neurochemistry* **148**:625–638. DOI: https://doi.org/10.1111/jn.14483, PMID: 29900534

Colonna M, Samaridis J. 1995. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. *Science* **268**:405–408. DOI: https://doi.org/10.1126/science.7716543, PMID: 7716543

Cox T, Lachmann H, Hollack C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A. 2000. Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. *Lancet* **355**:1481–1485. DOI: https://doi.org/10.1016/S0140-6736(00)02161-9, PMID: 10801168

Crusio WE. 2001. Genetic dissection of mouse exploratory behaviour. *Behavioural Brain Research* **125**:127–132. DOI: https://doi.org/10.1016/s0166-4328(01)00280-7, PMID: 11682103

Davies AJ, Kim HW, Gonzalez-Canal R, Choi J, Back SK, Roh SE, Johnson E, Gabriac M, Kim MS, Lee J, Lee JE, Kim YS, Bae YC, Kim SJ, Lee KM, Na HS, Riva P, Latremoliere A, Rinaldi S, Ugradini S, et al. 2019. Natural killer cells degenerate intact sensory afferents following nerve injury. *Cell* **176**:716-728.. DOI: https://doi.org/10.1016/j.cell.2018.12.022

Dick SA, Wong A, Hamidzada H, Nejat S, Nechanitsky R, Vohra S, Mueller B, Zaman R, Kantores C, Aroonoff L, Momen A, Nechanitsky D, Li WY, Ramachandran P, Crome SQ, Becher B, Cybulsky MI, Billia F, Keshavjee S, Mital S, et al. 2022. Three tissue resident macrophage subsets coexist across organs with conserved origins and life cycles. *Science Immunology* **7**:eabf7777. DOI: https://doi.org/10.1126/sciimmunol.abf7777, PMID: 34995099

Enquist IB, Lo Bianco C, Ooka A, Nilsson E, Månsson JE, Ehinger M, Richter J, Brady RO, Kirk D, Karlsson S. 2007. Murine models of acute neuropsychiatric Gaucher disease. *PNAS* **104**:17483–17488. DOI: https://doi.org/10.1073/pnas.0708086104, PMID: 17954912

Farfel-Becker T, Vitrer EB, Futterman AH. 2011. Animal models for Gaucher disease research. *Disease Models & Mechanisms* **4**:746–752. DOI: https://doi.org/10.1242/dmm.008185, PMID: 19154067

Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, Slichter CK, Miller HW, McElrath MJ, Prlic M, Linsley PS, Gottardo R. 2015. MAST: a flexible statistical framework for assessing transcriptional changes and...
characterizing heterogeneity in single-cell RNA sequencing data. Genome Biology 16:278. DOI: https://doi.org/10.1186/s13059-015-0844-5, PMID: 26653891

Gaetani L, Blenno K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. 2019. Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery, and Psychiatry 90:870–881. DOI: https://doi.org/10.1136/jnnp-2018-320106, PMID: 30967444

Gegg ME, Menozzi E, Schapira AHV. 2022. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments. Neurobiology of Disease 166:105663. DOI: https://doi.org/10.1016/j.nbd.2022.105663, PMID: 35183702

Grabowski GA, Antommaria AHM, Kolodny EH, Mistry PK. 2021. Gaucher disease: Basic and translational science needs for more complete therapy and management. Molecular Genetics and Metabolism 132:59–75. DOI: https://doi.org/10.1016/j.ymgme.2020.12.291, PMID: 33419694

Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne D, Nguyen L, Marshall JL, Chen F, Zhang F, Kaplan T, Regev A, Schwartz M. 2020. Disease-associated astrocytes in Alzheimer’s disease and aging. Nature Neuroscience 23:701–706. DOI: https://doi.org/10.1038/s41593-020-0624-8, PMID: 32341542

Hinton GE. 2002. Stochastic Neighbor Embedding. In Advances in Neural Information Processing Systems. NeurIPS Proceedings. p. 833–840.

Jongsma MLM, de Waard AA, Raaben M, Zhang T, Cabukusta B, Platzer R, Blomen VA, Xagara A, Verhoek M, Nelson J, Gabriel T, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, Benkert P, Ropele S, Enzinger C, Fazekas F, Schmidt R, Kuhle J. 2020. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nature Communications 11:812. DOI: https://doi.org/10.1038/s41467-020-14612-6, PMID: 32041951

Kanfer JN, Stephens MC, Singh H, Legler G. 1982. The Gaucher mouse. Progress in Clinical and Biological Research 95:627–644 PMID: 6812089.

Karlihofer FM, Ribaudo RK, Yokoyama WM. 1992. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358:66–70. DOI: https://doi.org/10.1038/358066a0, PMID: 1614533

Khalil M, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, Benkert P, Ropele S, Enzinger C, Fazekas F, Schmidt R, Kuhle J. 2020. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nature Communications 11:812. DOI: https://doi.org/10.1038/s41467-020-14612-6, PMID: 32041951

Kramer G, Wegdam W, Donker-Koopman W, Ottenhoff R, Gaspar P, Verhoek M, Nelson J, Gabriel T, Kallemijn W, Boot RG, Laman JD, Vissers JPC, Cox T, Pavlova E, Morant M, Aerts JM, van Eijk M. 2016. Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models. FEMS Open Bio 6:902–913. DOI: https://doi.org/10.1002/2211-5463.12078, PMID: 27642553

Lee JK, Tansey MG. 2013. Microglia isolation from adult mouse brain. Methods in Molecular Biology 1041:17–23. DOI: https://10.1007/978-1-62703-520-0_3, PMID: 23813365

Leoffler T, Schilcher I, Flunkert S, Hutter-Paier B. 2020. Neurofilament-light chain as biomarker of neurodegenerative and rare diseases with high translational value. Frontiers in Neuroscience 14:579. DOI: https://doi.org/10.3389/fnins.2020.00579, PMID: 32595447

Mahad D, Callahan MK, Williams KA, Ubogu EE, Kvisäkk P, Tucky B, Kidd G, Kingsbury GA, Chang A, Fox RJ, Mack M, Sniderman MB, Ravid R, Staugaitis SM, Stins MF, Ransohoff RM. 2006. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129:212–223. DOI: https://10.1093/brain/awh655, PMID: 16230319

Mendiola AS, Ryu JK, Bardelhe S, Meyer-Franke A, Ang KK-H, Wilson C, de Waard AA, Raaben M, Zhang T, Cabukusta B, Platzer R, Blomen VA, Xagara A, Verhoek M, Nelson J, Gabriel T, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, Benkert P, Ropele S, Enzinger C, Fazekas F, Schmidt R, Kuhle J. 2020. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nature Communications 11:812. DOI: https://doi.org/10.1038/s41467-020-14612-6, PMID: 32041951

Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, Zhang K, Keutzer J, Chuang WL, Zhang K, Mehta A, Packman S, Pastores G, Petakov M, Assoline S, Zhao H, Lin A, Mane S, Liu X, Peng YZ, Li JH, Agrawal M, Zhu LL, Blair HC, et al. 2010. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. PNAS 107:19473–19478. DOI: https://doi.org/10.1073/pnas.1003308107, PMID: 20962279

Mistry PK, Liu J, Sun L, Chuang WL, Yuen T, Yang R, Lu P, Zhang K, Li J, Keutzer J, Chastnik A, Mennone A, Boyer JL, Jain D, Brady RO, New MI, Zaidi M. 2014. Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. PNAS 111:4934–4939. DOI: https://10.1073/pnas.1400768111, PMID: 24639522

Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Krishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N. 2017a. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of algulcerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. American Journal of Hematology 92:929–939. DOI: https://doi.org/10.1002/ajh.24801, PMID: 28569047

Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris H, Ghosn M, Mehta A, Packman S, Pastores G, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Gaemers SJM, Tayag R, Peterschmitt MJ. 2017b. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial. American Journal of Hematology 92:1170–1176. DOI: https://doi.org/10.1002/ajh.24877, PMID: 28762527
Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, Pastores GM, Yang R, Keutzer J, Zhang K, Mistry PK. 2016. Glucosylphosphingosine is a key biomarker of Gaucher disease. American Journal of Hematology 91:1082–1089. DOI: https://doi.org/10.1002/ajh.24491, PMID: 27441734

Nagata M, Izumi Y, Ishikawa E, Kiyotake R, Doi R, Iwai S, Omahdi Z, Yamaji T, Miyamoto T, Bamba T, Yamasaki S. 2017. Intracellular metabolite β-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity. PNAS 114:E3285–E3294. DOI: https://doi.org/10.1073/pnas.1618331114, PMID: 28373578

Nair S, Boddupalli CS, Verma R, Liu J, Yang R, Pastores GM, Mistry PK, Dhodapkar MV. 2015. Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. Blood 125:1256–1271. DOI: https://doi.org/10.1182/blood-2014-09-600270, PMID: 25499455

Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV. 2016. Clonal immunoglobulin against lysolipids in the origin of myeloma. The New England Journal of Medicine 374:555–561. DOI: https://doi.org/10.1056/NEJMoa1508808, PMID: 26863356

Pandey MK, Burrow TA, Rani R, Martin LJ, Witte D, Setchell KD, Mckay MA, Magnusen AF, Zhang W, Liou B, Köhl J, Grabowski GA. 2017. Complement drives glucosylceramide accumulation and tissue infiltration in Gaucher disease. Nature 543:108–112. DOI: https://doi.org/10.1038/nature21368, PMID: 28225753

Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. 2018. Lysosomal storage diseases. Nature Reviews. Disease Primers 4:27. DOI: https://doi.org/10.1038/s41572-018-0025-4, PMID: 30275469

Satija R, Farrell JA, Gennert D, Schier AF, Regev A. 2015. Spatial reconstruction of single-cell gene expression data. Nature Biotechnology 33:495–502. DOI: https://doi.org/10.1038/nbt.3192

Schiffmann R, Fitzgibbon EJ, Harris C, DeVeile D, Davies EH, Mistry P, Crawford N, Gaemers S, Ji A, Peterschmitt MJ, Sharma J, Zhang Q, Fischer T. 2020. Venglustat combined with imiglucerase positively affects neurological features and brain connectivity in adults with Gaucher disease type 3. Molecular Genetics and Metabolism 129:S144–S145. DOI: https://doi.org/10.1016/j.ymgme.2019.11.382

Serrano-Pozo A, Das S, Hyman BT. 2021. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. The Lancet. Neurology 20:68–80. DOI: https://doi.org/10.1016/S1474-4422(20)30412-9, PMID: 33340485

Shayman JA. 2010. Eliglustat tartrate: Glucosylceramide synthase inhibitor treatment of type 1 gaucher disease. Drugs of the Future 35:613–620. DOI: https://doi.org/10.1056/NEJMoa1508808, PMID: 25499455

Shibuya Y, Kumar KK, Mader MM-D, Yoo Y, Ayala LA, Zhou M, Mohra M, Neumayer G, Kumar I, Yamamoto R, Marcoux P, Liou B, Bennett FC, Nakauchi H, Sun Y, Chen X, Hepper FL, Wyss-Coray T, Südhof TC, Wernig M. 2022. Treatment of a genetic brain disease by CNS-wide microglia replacement. Science Translational Medicine 14.eaai9945. DOI: https://doi.org/10.1126/scitranslmed.aai9945, PMID: 35294256

Shiner T, Mirielman A, Rosenblum Y, Kavé G, Weisz MG, Bar-Shira A, Gurevich T, On-Urtragere A, Giladi N, Bregman N. 2021. The effect of gba mutations and apoe polymorphisms on dementia with lewy bodies in ashkenazi jews. Journal of Alzheimer’s Disease 80:1221–1229. DOI: https://doi.org/10.3233/JAD-201295, PMID: 33641518

Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Brice A, Chan CM, Clark LN, Condrorey C, McAvoy EVD, Durr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, et al. 2009. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. The New England Journal of Medicine 361:1651–1661. DOI: https://doi.org/10.1056/NEJMoa0901281

Sidransky E, Lopez G. 2012. The link between the GBA gene and parkinsonism. The Lancet. Neurology 11:986–998. DOI: https://doi.org/10.1016/S1474-4422(12)70190-4, PMID: 23079555

Takizawa H, Regoes RR, Boddupalli CS, Bonhoeffer S, Manz MG. 2011. Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. The Journal of Experimental Medicine 208:273–284. DOI: https://doi.org/10.1084/jem.20101643, PMID: 21300914

Vardi A, Ben-Dor S, Cho SM, Kalinke U, Spanier J, Futerman AH. 2020. Mice defective in interferon signaling help distinguish between primary and secondary pathological pathways in a mouse model of neuronal forms of Gaucher disease. Journal of Neuroinflammation 17:265. DOI: https://doi.org/10.1186/s12974-020-01934-x, PMID: 32892753

Vincent BD, Guillaume JL, Lambotte R, Lefebvre E. 2008. Fast unfolding of communities in large networks. Journal of Statistical Mechanics 10:10008. DOI: https://doi.org/10.1088/1742-5468/2008/10/P10008

Vitner EB, Dekel H, Zigdon H, Shachar T, Farfel-Becker T, Eilam R, Karlsson S, Futerman AH. 2020. Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses. Human Molecular Genetics 19:3583–3590. DOI: https://doi.org/10.1093/hmg/ddq273, PMID: 20616152

Vitner EB, Vardi A, Cox TM, Futerman AH. 2015. Emerging therapeutic targets for Gaucher disease. Expert Opinion on Therapeutic Targets 19:321–334. DOI: https://doi.org/10.1517/14728222.2014.981530, PMID: 25416676

Walzer T, Chioussone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, Jacques Y, Baratin M, Tomasello E, Vivier E. 2007. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nature Immunology 8:1337–1344. DOI: https://doi.org/10.1038/ni1523, PMID: 17965716

Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, Ward M, Siddiqui O, Paul R, Gilfillan S, Ibrahim A, Rhinn H, Tassi I, Rosenthal A, Schwabe T, Colonna M. 2020. Anti-human TREM2 induces microglia proliferation
and reduces pathology in an Alzheimer's disease model. The Journal of Experimental Medicine 217:e20200785. DOI: https://doi.org/10.1084/jem.20200785, PMID: 32579671.

Weinhofer I, Rommer P, Zierfuss B, Altmann P, Foiani M, Heslegrave A, Zetterberg H, Gleiss A, Musolino PL, Gong Y, Forss-Petter S, Berger T, Eichler F, Aubourg P, Kohler W, Berger J. 2021. Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy. Nature Communications 12:1816. DOI: https://doi.org/10.1038/s41467-021-22114-2.

Wilson MW, Shu L, Hinkovska-Galcheva V, Jin Y, Rajeswaran W, Abe A, Zhao T, Luo R, Wang L, Wen B, Liou B, Fannin V, Sun D, Sun Y, Shayman JA, Larsen SD. 2020. Optimization of eliglustat-based glucosylceramide synthase inhibitors as substrate reduction therapy for gaucher disease type 3. ACS Chemical Neuroscience 11:3464–3473. DOI: https://doi.org/10.1021/acschemneuro.0c00558, PMID: 33035424.

Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, Morrison A, Lwin A, Colegial C, Allman JM, Schiﬀmann R. 2004. Neuropathology provides clues to the pathophysiology of Gaucher disease. Molecular Genetics and Metabolism 82:192–207. DOI: https://doi.org/10.1016/j.ymgme.2004.04.011, PMID: 15234332.

Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, Strauss-Ayali D, Viukov S, Guiliams M, Misharin A, Hume DA, Perlman H, Malissen B, Zelzer E, Jung S. 2013. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38:79–91. DOI: https://doi.org/10.1016/j.immuni.2012.12.001, PMID: 23273845.

Zigdon H, Savidor A, Levin Y, Meshcheriakova A, Schiﬀmann R, Futerman AH. 2015. Identiﬁcation of a biomarker in cerebrospinal ﬂuid for neuronopathic forms of Gaucher disease. PLOS ONE 10:e0120194. DOI: https://doi.org/10.1371/journal.pone.0120194, PMID: 25775479.